WO2009012039A2 - Crystalline polymorphs - Google Patents
Crystalline polymorphs Download PDFInfo
- Publication number
- WO2009012039A2 WO2009012039A2 PCT/US2008/068558 US2008068558W WO2009012039A2 WO 2009012039 A2 WO2009012039 A2 WO 2009012039A2 US 2008068558 W US2008068558 W US 2008068558W WO 2009012039 A2 WO2009012039 A2 WO 2009012039A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- another embodiment
- embodiment provides
- pharmaceutical composition
- animal
- Prior art date
Links
- 238000000034 method Methods 0.000 claims abstract description 2367
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 1264
- 239000000203 mixture Substances 0.000 claims abstract description 133
- 230000008569 process Effects 0.000 claims abstract description 12
- 241001465754 Metazoa Species 0.000 claims description 1180
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 261
- 239000008103 glucose Substances 0.000 claims description 260
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 258
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 146
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 144
- 230000002440 hepatic effect Effects 0.000 claims description 140
- 230000004110 gluconeogenesis Effects 0.000 claims description 137
- 206010022489 Insulin Resistance Diseases 0.000 claims description 134
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 134
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 133
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 claims description 131
- 208000011661 metabolic syndrome X Diseases 0.000 claims description 131
- 201000001421 hyperglycemia Diseases 0.000 claims description 129
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 124
- 201000010099 disease Diseases 0.000 claims description 122
- 239000008280 blood Substances 0.000 claims description 120
- 210000004369 blood Anatomy 0.000 claims description 120
- 230000032393 negative regulation of gluconeogenesis Effects 0.000 claims description 110
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 103
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 42
- 150000001875 compounds Chemical class 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 20
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 claims 1
- 101710099475 3'-phosphoadenosine 5'-phosphate phosphatase Proteins 0.000 claims 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims 1
- 101710196411 Fructose-1,6-bisphosphatase Proteins 0.000 claims 1
- 101710186733 Fructose-1,6-bisphosphatase, chloroplastic Proteins 0.000 claims 1
- 101710109119 Fructose-1,6-bisphosphatase, cytosolic Proteins 0.000 claims 1
- 101710198902 Fructose-1,6-bisphosphate aldolase/phosphatase Proteins 0.000 claims 1
- 239000012296 anti-solvent Substances 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 abstract description 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 259
- 229960001031 glucose Drugs 0.000 description 259
- 206010012601 diabetes mellitus Diseases 0.000 description 33
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 33
- 229940125396 insulin Drugs 0.000 description 17
- 102000004877 Insulin Human genes 0.000 description 16
- 108090001061 Insulin Proteins 0.000 description 16
- 208000011580 syndromic disease Diseases 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 230000002503 metabolic effect Effects 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 238000013270 controlled release Methods 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 5
- 230000003914 insulin secretion Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 102000012195 Fructose-1,6-bisphosphatases Human genes 0.000 description 3
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000004190 glucose uptake Effects 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- -1 5-ketothiazole compound Chemical class 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- 201000005948 Donohue syndrome Diseases 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010023379 Ketoacidosis Diseases 0.000 description 2
- 208000007976 Ketosis Diseases 0.000 description 2
- 241000763212 Lype Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 102100041030 Pancreas/duodenum homeobox protein 1 Human genes 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 208000004104 gestational diabetes Diseases 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 208000003606 Congenital Rubella Syndrome Diseases 0.000 description 1
- 206010053547 Congenital generalised lipodystrophy Diseases 0.000 description 1
- 201000006705 Congenital generalized lipodystrophy Diseases 0.000 description 1
- 206010010619 Congenital rubella infection Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000638044 Homo sapiens Neurogenic differentiation factor 1 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010052341 Impaired insulin secretion Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 208000017924 Klinefelter Syndrome Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008972 Laurence-Moon syndrome Diseases 0.000 description 1
- 208000035369 Leprechaunism Diseases 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100032063 Neurogenic differentiation factor 1 Human genes 0.000 description 1
- 101710144033 Pancreas/duodenum homeobox protein 1 Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- 208000016140 Rabson-Mendenhall syndrome Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 206010001323 adrenal adenoma Diseases 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- 208000014594 aldosterone-producing adenoma with seizures and neurological abnormalities Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- UBWYRXFZPXBISJ-UHFFFAOYSA-L calcium;2-hydroxypropanoate;trihydrate Chemical compound O.O.O.[Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O UBWYRXFZPXBISJ-UHFFFAOYSA-L 0.000 description 1
- ZHZFKLKREFECML-UHFFFAOYSA-L calcium;sulfate;hydrate Chemical compound O.[Ca+2].[O-]S([O-])(=O)=O ZHZFKLKREFECML-UHFFFAOYSA-L 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000025938 carbohydrate utilization Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960000673 dextrose monohydrate Drugs 0.000 description 1
- GDLBFKVLRPITMI-UHFFFAOYSA-N diazoxide Chemical compound ClC1=CC=C2NC(C)=NS(=O)(=O)C2=C1 GDLBFKVLRPITMI-UHFFFAOYSA-N 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- 229940064790 dilantin Drugs 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 210000003020 exocrine pancreas Anatomy 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000022215 lipoatrophic diabetes Diseases 0.000 description 1
- 201000009099 lipoatrophic diabetes mellitus Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001235 maturity-onset diabetes of the young type 6 Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- CLKZWXHKFXZIMA-UHFFFAOYSA-N pyrinuron Chemical compound C1=CC([N+](=O)[O-])=CC=C1NC(=O)NCC1=CC=CN=C1 CLKZWXHKFXZIMA-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Definitions
- the present invention relates to crystalline polymorphs of a phosphorus-containing 5-ketothiazole compound that is a potent inhibitor of fructose- 1,6-bisphosphatase (FBPase) and pharmaceutical compositions thereof as well as methods of making and using the same.
- FBPase fructose- 1,6-bisphosphatase
- a compound may exist in an amorphous state or in a crystalline state.
- a crystalline form of an API may be polymorphic.
- a polymorph is a compound of a defined chemical composition that exists in more than one molecular arrangement or configuration in the solid state.
- the present invention provides for novel crystalline polymorphic forms, or polymorphs, (Forms A-E) of 2-amino-5-(2,2-dimethylpropionyl)-4- ⁇ [5-(N,N-(2-ethoxy- carbonylprop-2-yl)phosphonamido] furan-2-yl ⁇ thiazole (the compound of Formula I) and pharmaceutical compositions and medicaments of the same. Further provided are methods of using the polymorph Forms A-E of the compound of Formula I (herein after, simply Forms A-E) in the treatment of patients in need thereof. The invention further provides for processes of making Forms A-E. BRIEF DESCRIPTION OF THE DRAWINGS
- Figure 3. X-ray diffraction pattern of Form B.
- Figure 4. XRPD pattern of Form B (calculated pattern from single crystal data).
- FIG. 5 Comparison of the experimental to the calculated XRPD pattern of Form B.
- the top pattern is an experimental XPRD.
- the bottom pattern is calculated form single crystal data.
- Animal includes birds and mammals, in one embodiment a mammal, including a dog, cat, cow, horse, goat, sheep, pig or human. In one embodiment the animal is a human. In another embodiment the animal is a male. In another embodiment the animal is a female.
- ''Diabetes refers to a heterogeneous group of disorders that share glucose intolerance in common. It refers to disorders in which carbohydrate utilization is reduced and that of lipid and protein enhanced; and may be characterized by hyperglycemia, glycosuria, ketoacidosis, neuropathy or nephropathy, increased hepatic glucose production, insulin resistance in various tissues, insufficient insulin secretion and enhanced or poorly controlled glucagon secretion from the pancreas.
- Symptoms of marked hyperglycemia include polyuria, polydipsia, weight loss, sometimes with polyphagia, and blurred vision.
- the vast majority of cases of diabetes fall into two broad etiopatho genetic categories.
- type 1 diabetes the cause is an absolute deficiency of insulin secretion.
- Individuals at increased risk of developing this type of diabetes can often be identified by serological evidence of an autoimmune pathologic process occurring in the pancreatic islets and by genetic markers.
- type 2 diabetes the cause is a combination of resistance to insulin action and an inadequate compensatory insulin secretory response.
- a degree of hyperglycemia sufficient to cause pathologic and functional changes in various target tissues, but without clinical symptoms, may be present for a long period of time before diabetes is detected.
- this asymptomatic period it is possible to demonstrate an abnormality in carbohydrate metabolism by measurement of plasma glucose in the fasting state or after a challenge with an oral glucose load.
- Criteria for the diagnosis of diabetes include: 1. Symptoms of diabetes plus casual plasma glucose concentration 200 mg/dl (1 1.1 mmol/1).
- FPG 126 mg/dl (7.0 mmol/1). Fasting is defined as no caloric intake for at least 8 h; or
- Etiologic classification of diabetes mellitus are as follows: I. Type 1 diabetes ( ⁇ -cell destruction, usually leading to absolute insulin deficiency) A. Immune mediated B. Idiopathic II. Type 2 diabetes (may range from predominantly insulin resistance with relative insulin deficiency to a predominantly secretory defect with insulin resistance) ITI. Other specific types
- GDM Gestational diabetes mellitus
- Insulin resistance is defined clinically as the impaired ability of a known quantity of exogenous or endogenous insulin to increase whole body glucose uptake and utilization.
- IGT Internet glucose tolerance
- a condition known to precede the development of overt Type 2 diabetes It is characterized by abnormal blood glucose excursions following a meal.
- the current criteria for the diagnosis of IGT are based on 2-h plasma glucose levels post a 75g oral glucose test (144-199 mg/dL). Although variable from population to population studied, IGT progresses to full-blown NIDDM at a rate of 1.5 to
- IGT is an independent risk factor for the development of cardiovascular disease.
- Metabolic Syndrome X or "The Metabolic Syndrome” is characterized by a group of metabolic risk factors in one person. They include:
- Insulin resistance or glucose intolerance the body can't properly use insulin or blood sugar
- Prothrombotic state e.g., high fibrinogen or plasminogen activator inhibitor [-1J in the blood
- Proinflammatory state e.g., elevated high-sensitivity C -reactive protein in the blood
- “Metabolic Syndrome” or “Metabolic Syndrome X” is identified by the presence of three or more of these components: • Central obesity as measured by waist circumference:
- Fasting glucose greater than or equal to 110 mg/dL ''Preventing includes a slowing of the progress or development of a disease before onset or precluding onset of a disease.
- Therapeutically effective amount means an amount of a compound or a combination of compounds that ameliorates, attenuates or eliminates one or more of the symptoms of a particular disease or condition or prevents, modifies, or delays the onset of one or more of the symptoms of a particular disease or condition.
- Treatment includes a slowing of the progress or development of a disease after onset or actually reversing some or all of the disease affects. Treatment also includes palliative treatment.
- Type 1 diabetes (formerly known as “childhood,” “juvenile,” “insulin-dependent” diabetes) is a form of diabetes characterized by an absolute deficiency of insulin secretion. Individuals at increased risk of developing this type of diabetes can often be identified by serological evidence of an autoimmune pathologic process occurring in the pancreatic islets and by genetic markers. Type 1 diabetes may be caused by immune mediated beta-cell destruction, usually leading to absolute insulin deficiency or may be idiopathic, having no known etiologies.
- Type 2 diabetes refers to a heterogeneous disorder characterized by impaired insulin secretion by the pancreas and insulin resistance in tissues such as the liver, muscle and adipose tissue.
- the manifestations of the disease include one or more of the following: impaired glucose tolerance, fasting hyperglycemia, glycosuria, decreased levels of insulin, increased levels of glucagon, increased hepatic glucose output, reduced hepatic glucose uptake and glycogen storage, reduced whole body glucose uptake and utilization, dyslipidemia, fatty liver, ketoacidosis, microvascular diseases such as retinopathy, nephropathy and neuropathy, and macrovascular diseases such as coronary heart disease.
- the present invention relates to polymorph Forms A-E.
- the invention provides for a composition consisting of, consisting essentially of or comprising Forms A.
- the invention provides for a composition consisting of, consisting essentially of or comprising Form B. In one embodiment, the invention provides for a composition consisting of, consisting essentially of or comprising Form C.
- the invention provides for a composition consisting of, consisting essentially of or comprising Form D.
- the invention provides for a composition consisting of. consisting essentially of or comprising Form E.
- Another embodiment provides for a composition comprising Forms A and B.
- Another embodiment provides for a composition comprising Forms A and C.
- Another embodiment provides for a composition comprising Forms A and D.
- Another embodiment provides for a composition comprising Forms A and E. Another embodiment provides for a composition comprising Forms B and C.
- Another embodiment provides for a composition comprising Forms B and D.
- Another embodiment provides for a composition comprising Forms B and E.
- Another embodiment provides for a composition comprising Forms C and D.
- Another embodiment provides for a composition comprising Forms C and E. Another embodiment provides for a composition comprising Forms D and E.
- Another embodiment provides for a composition comprising Formula I, wherein at least 50% of said Formula 1 is Form A.
- Another embodiment provides for a composition comprising Formula 1. wherein at least 70% of said Formula I is Form A.
- Another embodiment provides for a composition comprising Formula I, wherein at least 75% of said Formula 1 is Form A.
- Another embodiment provides for a composition comprising Formula 1, wherein at least 80% of said Formula 1 is Form A.
- Another embodiment provides for a composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
- Another embodiment provides for a composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
- Another embodiment provides for a composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
- Another embodiment provides for a composition comprising Formula 1, wherein at least 50% of said Formula I is Form B.
- Another embodiment provides for a composition comprising Formula I, wherein at least 70%) of said Formula I is Form B. Another embodiment provides for a composition comprising Formula 1, wherein at least 75%o of said Formula I is Form B.
- compositions comprising Formula I, wherein at least 80% of said Formula I is Form B.
- Another embodiment provides for a composition comprising Formula 1, wherein at least 90% of said Formula 1 is Form B.
- Another embodiment provides for a composition comprising Formula I, wherein at least 95%o of said Formula 1 is Form B.
- Another embodiment provides for a composition comprising Formula I, wherein at least 98% of said Formula I is Form B. Another embodiment provides for a composition comprising Formula I, wherein at least 50%) of said Formula I is Form C.
- Another embodiment provides for a composition comprising Formula I, wherein at least 70%o of said Formula I is Form C. Another embodiment provides for a composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
- Another embodiment provides for a composition comprising Formula I, wherein at least 80% of said Formula I is Form C. Another embodiment provides for a composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
- Another embodiment provides for a composition comprising Formula 1, wherein at least 95% of said Formula I is Form C.
- Another embodiment provides for a composition comprising Formula 1, wherein at least 98% of said Formula I is Form C.
- Another embodiment provides for a composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
- Another embodiment provides for a composition comprising Formula 1. wherein at least 70% of said Formula I is Form D. Another embodiment provides for a composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
- compositions comprising Formula I, wherein at least 80% of said Formula 1 is Form D.
- Another embodiment provides for a composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
- Another embodiment provides for a composition comprising Formula 1, wherein at least 95% of said Formula 1 is Form D.
- Another embodiment provides for a composition comprising Formula I 5 wherein at least 98%) of said Formula I is Form D.
- Another embodiment provides for a composition comprising Formula I, wherein at least 50% of said Formula 1 is Form E.
- Another embodiment provides for a composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
- Another embodiment provides for a composition comprising Formula 1, wherein at least 75% of said Formula I is Form E.
- compositions comprising Formula I, wherein at least 80% of said Formula 1 is Form E.
- Another embodiment provides for a composition comprising Formula I, wherein at least 90% of said Formula I is Form E. Another embodiment provides for a composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
- Another embodiment provides for a composition comprising Formula I, wherein at least 98% of said Formula I is Form E. Another embodiment provides for a composition comprising Formula I, wherein said
- Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula 1 is Form ⁇ .
- compositions comprising Formula 1, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula I is Form A.
- compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula I is Form A.
- compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form A.
- compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula 1 is Form A.
- compositions comprising Formula 1, wherein said
- Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula I is Form A.
- compositions comprising Formula I. wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula 1 is Form A.
- compositions comprising Formula I. wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula I is Form A.
- compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 2% of said Formula I is Form A.
- compositions comprising Formula I, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 1% of said Formula I is Form A.
- compositions comprising Formula 1, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula I is Form B.
- compositions comprising Formula T, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula I is Form B.
- compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula I is Form B.
- compositions comprising Formula I, wherein said
- Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form B.
- compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula 1 is Form B.
- compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula I is Form B.
- compositions comprising Formula 1, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula I is Form B.
- compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula I is Form B.
- compositions comprising Formula I, wherein said
- Formula I comprises at least one crystalline form selected from Forms A-E. and wherein less than 2% of said Formula I is Form B.
- compositions comprising Formula 1, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 1 % of said Formula I is Form B.
- compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula I is Form C.
- compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula 1 is Form C.
- compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula I is Form C.
- compositions comprising Formula T, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula i is Form C.
- compositions comprising Formula I. wherein said
- Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula 1 is Form C.
- compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula I is Form C.
- compositions comprising Formula 1, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula I is Form C.
- compositions comprising Formula 1, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula I is Form C.
- compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 2% of said Formula I is Form C.
- compositions comprising Formula I, wherein said
- Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 1% of said Formula 1 is Form C.
- compositions comprising Formula I, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula I is Form D.
- compositions comprising Formula I, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula I is Form D.
- compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula I is Form D.
- compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form D.
- compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula I is Form D.
- compositions comprising Formula I, wherein said
- Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula I is Form D.
- compositions comprising Formula 1, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula I is Form D.
- compositions comprising Formula I. wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula I is Form D.
- compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 2% of said Formula I is Form D.
- compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 1 % of said Formula I is Form D.
- compositions comprising Formula T, wherein said
- Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula I is Form E.
- compositions comprising Formula I, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula I is Form E.
- compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula I is Form E.
- compositions comprising Formula 1. wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form E.
- compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula I is Form E.
- compositions comprising Formula I, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula I is Form E.
- compositions comprising Formula I. wherein said
- Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula I is Form E.
- compositions comprising Formula I, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula I is Form E.
- compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 2% of said Formula I is Form E.
- compositions comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 1% of said Formula I is Form E.
- composition of the present invention is a pharmaceutical composition comprising Form A and a pharmaceutically acceptable excipient.
- composition of the present invention is a pharmaceutical composition comprising Form B and a pharmaceutically acceptable excipient.
- composition of the present invention is a pharmaceutical composition comprising Form C and a pharmaceutically acceptable excipient.
- a composition of the present invention is a pharmaceutical composition comprising Form D and a pharmaceutically acceptable excipient. In another embodiment, a composition of the present invention is a pharmaceutical composition comprising Form E and a pharmaceutically acceptable excipient.
- Another embodiment provides for a pharmaceutical composition comprising Forms A and B and a pharmaceutically acceptable excipient. Another embodiment provides for a pharmaceutical composition comprising Forms A and C and a pharmaceutical) y acceptable cxcipient.
- Another embodiment provides for a pharmaceutical composition comprising Forms A and D and a pharmaceutically acceptable excipicnt. Another embodiment provides for a pharmaceutical composition comprising Forms A and E and a pharmaceutically acceptable excipient.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Forms B and C and a pharmaceutically acceptable excipient.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Forms B and D and a pharmaceutically acceptable excipient.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Forms B and E and a pharmaceutically acceptable excipient.
- Another embodiment provides for a pharmaceutical composition comprising Forms C and D and a pharmaceutically acceptable excipient. Another embodiment provides for a pharmaceutical composition comprising Forms C and E and a pharmaceutically acceptable excipient.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Forms D and E and a pharmaceutically acceptable excipient.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 50% of said Formula I is Form A.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient. wherein at least 80% of said Formula 1 is Form A.
- Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 90% of said Formula I is Form A.
- Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 95% of said Formula I is Form A.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 98% of said Formula 1 is Form A.
- Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 50% of said Formula I is Form B.
- Another embodiment provides for a pharmaceutical composition comprising Formula
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 75% of said Formula 1 is Form B.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 80% of said Formula 1 is Form B.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 90% of said Formula I is Form B.
- Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 95% of said Formula I is Form B.
- Another embodiment provides for a pharmaceutical composition comprising Formula
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 50% of said Formula 1 is Form C.
- Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 70% of said Formula I is Form C.
- Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 75% of said Formula I is Form C.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 80% of said Formula I is Form C.
- Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 90% of said Formula I is Form C.
- Another embodiment provides for a pharmaceutical composition comprising Formula
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 98% of said Formula 1 is Form C.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 50% of said Formula I is Form D.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 70% of said Formula I is Form D.
- Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 75% of said Formula 1 is Form D.
- Another embodiment provides for a pharmaceutical composition comprising Formula
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 90% of said Formula I is Form D.
- Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 95% of said Formula I is Form D.
- Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 98% of said Formula I is Form D.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 50% of said Formula 1 is Form E.
- Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 70% of said Formula 1 is Form H.
- Another embodiment provides for a pharmaceutical composition comprising Formula
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 80% of said Formula I is Form E.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 90% of said Formula I is Form E.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 95% of said Formula I is Form E.
- Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 98% of said Formula I is Form E.
- Another embodiment provides for a pharmaceutical composition comprising Formula
- Formula I comprises at least one crystalline form selected from Forms A-E. and wherein less than 50% of said Formula I is Form A.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula 1 is Form A.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-H, and wherein less than 30% of said Formula I is Form ⁇ .
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form A.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula 1 is Form A.
- Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula 1 is Form A.
- Another embodiment provides for a pharmaceutical composition comprising Formula
- Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula I is Form A.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula I is Form A.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 2% of said Formula I is Form A.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 1% of said Formula I is Form A.
- Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula 1 is Form B.
- Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula I is Form B.
- Another embodiment provides for a pharmaceutical composition comprising Formula
- Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula I is Form B.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form B.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula I is Form B.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula 1 is Form B.
- Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula I is Form B.
- Another embodiment provides for a pharmaceutical composition comprising Formula
- Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula I is Form B.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 2% of said Formula I is Form B.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 1% of said Formula I is Form B.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula T comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula I is
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient.
- said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula I is Form C.
- Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula I is Form C.
- Another embodiment provides for a pharmaceutical composition comprising Formula
- Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form C.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula I is Form C.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula I is Form C.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula I is Form C.
- Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula 1 is Form C.
- Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms ⁇ -E, and wherein less than 2% of said Formula 1 is Form C.
- Another embodiment provides for a pharmaceutical composition comprising Formula
- Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 1% of said Formula I is Form C.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula 1 is Form D.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula I is Form D.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient.
- said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula 1 is Form D.
- Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form D.
- a pharmaceutical composition comprising Formula I
- Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula 1 is Form D.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula 1 is Form D.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula 1 is Form D.
- compositions comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula 1 is Form D,
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 2% of said Formula I is Form D.
- Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 1% of said Formula I is Form D.
- a pharmaceutical composition comprising Formula I
- Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula I is Form E.
- compositions comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula I is Form E,
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula I is Form E.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form E.
- Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula 1 is Form E.
- Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula 1 is Form E.
- Another embodiment provides for a pharmaceutical composition comprising Formula
- Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula I is Form E.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula 1 is Form E.
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E. and wherein less than 2% of said Formula I is
- Another embodiment provides for a pharmaceutical composition
- a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 1% of said Formula I is Form E.
- Another embodiment provides for the use of any one or more of Forms A-E for the manufacture of a medicament for the prevention, treatment or reduction of the time to onset of a disease or clinical condition for which an FBPase inhibitor(s) is indicated.
- Another embodiment provides for the use of any one or more of Forms A-E in the manufacture of a medicament for the treatment, prevention or reduction of the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels.
- Another embodiment provides for a method of treating, preventing or reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of Formula I selected from Forms A-E.
- Another embodiment provides for a method of for treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
- Another embodiment provides for a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels. the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form A.
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogcncsis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form A.
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said f ormula I is Form B.
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula 1 is
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is
- Another embodiment provides a method oO ' treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula 1 is
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula T, wherein at least 99% of said Formula I is Form C.
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form D.
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form D.
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula 1 is
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is
- Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said
- Formula I is Form A.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1. wherein at least 70% of said
- Formula I is Form A.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gl ⁇ coneogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form ⁇ .
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula I is Form A.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula i is Form A.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form A.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula T, wherein at least 98% of said Formula I is Form A.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 99% of said Formula I is Form A.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I 5 wherein at least 70% of said
- Formula I is Form B.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said
- Formula I is Form B.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said
- Formula 1 is Form B.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said
- Formula I is Form B.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels. the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said
- Formula I is Form B.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said
- Formula I is Form B.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 99% of said Formula I is Form B.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said
- Formula I is Form C.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said
- Formula I is Form C.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said
- Formula I is Form C.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said
- Formula 1 is Form C.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 90% of said
- Formula 1 is Form C.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said
- Formula I is Form C.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconcogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula 1 is Form C.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula 1 is Form C.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form D.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form D.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula I is Form D.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form D.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said
- Formula 1 is Form D.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said
- Formula I is Form D.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said
- Formula 1 is Form D.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said
- Formula 1 is Form E.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said
- Formula I is Form E.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said
- Formula 1 is Form E.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form R.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels. the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said
- Formula I is Form E.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said
- Formula 1 is Form E.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 98% of said
- Formula I is Form E.
- Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said
- Formula I is Form E.
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 75% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 80% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form A.
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form A.
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula 1 is Form A.
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form B.
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula L wherein at least
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form C.
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula 1 is Form C.
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 80% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula i, wherein at least
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula I is Form E.
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of treating, preventing or reducing the time to onset of Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of Formula I selected from Forms A-E.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
- Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a Form C.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
- Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form A.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
- Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
- Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 98% of said Formula 1 is Form A.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form B.
- Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
- Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form B.
- Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form B.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B.
- Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form B.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form B.
- Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form C.
- Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C
- Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form C.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C .
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form D,
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 70% of said Formula I is Form D.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is Form D.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form D.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form D.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula 1 is Form E.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form E.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form E.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is Form E.
- Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form E.
- Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
- Another embodiment pro ⁇ des a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula 1 is Form E.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form A.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form A.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form A.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form A.
- Another embodiment provides a method of preventing Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 99% of said Formula 1 is Form A.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeuticall) effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form B.
- Another embodiment provides a method of preventing Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form B.
- Another embodiment provides a method of preventing Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form B.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B.
- Another embodiment provides a method of preventing Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form B.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula 1 is Form B.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 99% of said Formula I is Form B.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 70% of said Formula I is Form C.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form C.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form C.
- Another embodiment provides a method of preventing Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
- Another embodiment provides a method of preventing Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
- Another embodiment provides a method of preventing lype I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form D.
- Another embodiment provides a method of preventing Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I 5 wherein at least 75% of said Formula I is Form D.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
- Another embodiment provides a method of preventing fype I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I 5 wherein at least 95% of said Formula I is Form D.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form D.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form E.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I 5 wherein at least 70% of said Formula I is Form E.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E,
- Another embodiment provides a method of preventing ' lype I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form E.
- Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
- Another embodiment provides a method of reducing the time to onset of Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula 1 is Form A.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula 1 is Form A.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form B.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 99% of said Formula 1 is Form B.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form C.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form C.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of Type ⁇ diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form D.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula i is Form D.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 99% of said Formula 1 is Form D.
- Another embodiment provides a method of reducing the time to onset of Type T diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form E.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula 1 is Form E.
- Another embodiment provides a method of reducing the time to onset of T>pe 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form E.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula i is Form E.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I 5 wherein at least 95% of said Formula I is Form E.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form H.
- Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form R.
- Another embodiment provides a method of treating, preventing or reducing the time to onset of Type 11 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of Formula I selected from Forms A-E.
- Another embodiment provides a method of treating Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
- Another embodiment provides a method of treating Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B. Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B. Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 80% of said Formula I is Form A.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form B.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B .
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is Form B.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 95% of said Formula I is Form B.
- Another embodiment provides a method of treating Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
- Another embodiment provides a method of treating Type 11 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula 1 is Form C.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutical! ⁇ ' effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form C.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 50% of said Formula I is Form D.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 75% of said Formula I is Form D.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
- Another embodiment provides a method of treating Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form E.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form E.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
- Another embodiment provides a method of treating Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, w r herein at least 98% of said Formula I is Form E.
- Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
- Another embodiment provides a method of preventing Type 11 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
- Another embodiment provides a method of preventing Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is Form A.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering Io an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
- Another embodiment provides a melhod of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form B.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B,
- Another embodiment provides a method of preventing Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is Form B.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula T, wherein at least 95% of said Formula I is
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 98% of said Formula I is Form B.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 50% of said Formula I is Form C.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form C.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
- Another embodiment provides a method of preventing Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form C.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form D.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 50% of said Formula I is Form E.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1. wherein at least 70% of said Formula I is Form E.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 90% of said Formula I is Form E.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form E.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
- Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form ⁇ .
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form ⁇ .
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
- Another embodiment provides a method of inducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form C.
- Another embodiment provides a method of reducing the time to onset of Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form C.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 70% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 99% of said Formula 1 is Form D.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Fo ⁇ n E.
- Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
- Another embodiment provides a method of treating, preventing or reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of Formula I selected from Forms A-E.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
- Another embodiment provides a method of preventing Metabolic Syndrome X 5 the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a Form C. Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D. Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Fo ⁇ n E.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I 5 wherein at least 98% of said Formula I is Form A.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form B.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form B.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I 5 wherein at least 99% of said Formula I is Form C.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I 5 wherein at least 50% of said Formula I is Form D.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Fo ⁇ nula I, wherein at least 80% of said Formula I is Fo ⁇ n D.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 90% of said Formula I is Form D.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form D.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Fonnula 1 is Form D.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form E,
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Fo ⁇ n E.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form E.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
- Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form A.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula I is Form B.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form B.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form B.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula 1 is Form B.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form C.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form D.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula 1 is Form D.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Fo ⁇ nula I is Form D.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pha ⁇ naceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pha ⁇ naceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
- Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form A.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X
- Syndrome X the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form A.
- Another embodiment provides a method of reducing the time to onset of Metabolic
- Syndrome X the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Fo ⁇ nula I, wherein at least 50% of said Fo ⁇ nula I is Form B.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form B.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form B.
- Another embodiment provides a method of reducing the time to onset of Metabolic
- Syndrome X the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form C.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form C.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of Metabolic
- Syndrome X the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of Metabolic
- Syndrome X the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Fo ⁇ n D.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form D.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of Metabolic
- Syndrome X the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 99% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form E.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X
- Syndrome X the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form E.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least
- Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 99% of said Formula I is Form E.
- Another embodiment provides a method of treating, preventing or reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of Formula I selected from Forms A-E.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pha ⁇ naceutical composition comprising Form D.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form A.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form A.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form A.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form A.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form A.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Fo ⁇ nula I is Form B.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form E.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
- Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form B.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form B.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form C.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form C.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Fo ⁇ nula I is Form C.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula 1 is Form D.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Fo ⁇ nula I is Form D.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
- Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula 1 is Form E.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pha ⁇ naceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula 1 is Form A.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form B.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pha ⁇ naceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form B.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form C.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula 1 is Form D.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula 1 is Form D.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form D.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form E.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Fo ⁇ nula I, wherein at least 70% of said Formula 1 is Form E.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form E.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form E.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
- Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
- Another embodiment provides a method of treating, preventing or reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of Formula 1 selected from Forms A-E.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form A.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form A.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form A.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form A.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form B.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form B.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form B.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 99% of said Formula I is Form B.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form C.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form C.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula 1 is Form C.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form E.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula I is Form E.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
- Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Fo ⁇ n A.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Fo ⁇ nula I is Form A.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Fo ⁇ nula I, wherein at least 99% of said Formula I is Form A.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form B.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form B.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form B.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula I is Form B.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula 1 is Form B.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form B.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form C.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form C.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form C.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I 5 wherein at least 99% of said Formula I is Form C.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form D.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form D.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula I is Form D.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form D.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form E.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
- Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula 1 is Form A.
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form A.
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form B.
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula 1 is Form B.
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form C.
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
- Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
Abstract
The present invention provides for crystalline forms of 2-amino-5-(2,2- dimethylpropionyl)-4-{[5-(N,N'-(2-ethoxycarbonylprop-2-yl)phosphonamido] furan-2-yl}thiazole and compositions thereof including pharmaceutical compositions. The present invention further provides for methods of using and processes for making the same.
Description
CRYSTALLINE POLYMORPHS
CROSS-REFERENCE TO RELATED APPLICATION
This application claims the benefit of U.S. Provisional Application Serial No.
60/949,681, filed July 13, 2007, the disclosure of which is hereby incorporated by reference in its entirety, including all figures, tables and amino acid or nucleic acid sequences.
FIELD OF THE INVENTION
The present invention relates to crystalline polymorphs of a phosphorus-containing 5-ketothiazole compound that is a potent inhibitor of fructose- 1,6-bisphosphatase (FBPase) and pharmaceutical compositions thereof as well as methods of making and using the same.
BACKGROUND OF THE INVENTION
Depending on the chemical nature of molecule, a compound may exist in an amorphous state or in a crystalline state. A crystalline form of an API may be polymorphic. A polymorph is a compound of a defined chemical composition that exists in more than one molecular arrangement or configuration in the solid state.
SUMMARY OF THE INVENTION
The present invention provides for novel crystalline polymorphic forms, or polymorphs, (Forms A-E) of 2-amino-5-(2,2-dimethylpropionyl)-4-{[5-(N,N-(2-ethoxy- carbonylprop-2-yl)phosphonamido] furan-2-yl}thiazole (the compound of Formula I) and pharmaceutical compositions and medicaments of the same. Further provided are methods of using the polymorph Forms A-E of the compound of Formula I (herein after, simply Forms A-E) in the treatment of patients in need thereof. The invention further provides for processes of making Forms A-E.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1. XRPD pattern of Form A.
Figure 2. DSC/TG data of Form A.
Figure 3. X-ray diffraction pattern of Form B. Figure 4. XRPD pattern of Form B (calculated pattern from single crystal data).
Figure 5. Comparison of the experimental to the calculated XRPD pattern of Form B. The top pattern is an experimental XPRD. The bottom pattern is calculated form single crystal data.
Figure 6. DSC/TG data of Form B.
Figure 7. DSC/TG data of Form C. Figure 8. XRPD pattern of Form C. Figure 9. DSC data of Form D.
Figure 10. XRPD pattern of Form D.
Figure 11. XRPD pattern of Forms A, B. C, and D (top to bottom, respectively).
Figure 12. XRPD pattern of Form E.
DETAILED DKSCRlP fION OF THE INVENTION
Definitions As used herein, the following terms are defined with the following meanings:
"Animal" includes birds and mammals, in one embodiment a mammal, including a dog, cat, cow, horse, goat, sheep, pig or human. In one embodiment the animal is a human. In another embodiment the animal is a male. In another embodiment the animal is a female.
''Diabetes" refers to a heterogeneous group of disorders that share glucose intolerance in common. It refers to disorders in which carbohydrate utilization is reduced and that of lipid and protein enhanced; and may be characterized by hyperglycemia, glycosuria, ketoacidosis, neuropathy or nephropathy, increased hepatic glucose production, insulin
resistance in various tissues, insufficient insulin secretion and enhanced or poorly controlled glucagon secretion from the pancreas.
Several pathogenic processes are involved in the development of diabetes. These range from autoimmune destruction of the beta-cells of the pancreas with consequent insulin deficiency to abnormalities that result in resistance to insulin action. The basis of the abnormalities in carbohydrate, fat, and protein metabolism in diabetes is deficient action of insulin on target tissues. Deficient insulin action results from inadequate insulin secretion and/or diminished tissue responses to insulin at one or more points in the complex pathways of hormone action. Impairment of insulin secretion and defects in insulin action frequently coexist in the same patient.
Symptoms of marked hyperglycemia include polyuria, polydipsia, weight loss, sometimes with polyphagia, and blurred vision. The vast majority of cases of diabetes fall into two broad etiopatho genetic categories. In one category, type 1 diabetes, the cause is an absolute deficiency of insulin secretion. Individuals at increased risk of developing this type of diabetes can often be identified by serological evidence of an autoimmune pathologic process occurring in the pancreatic islets and by genetic markers. In the other, much more prevalent category, type 2 diabetes, the cause is a combination of resistance to insulin action and an inadequate compensatory insulin secretory response. In the latter category, a degree of hyperglycemia sufficient to cause pathologic and functional changes in various target tissues, but without clinical symptoms, may be present for a long period of time before diabetes is detected. During this asymptomatic period, it is possible to demonstrate an abnormality in carbohydrate metabolism by measurement of plasma glucose in the fasting state or after a challenge with an oral glucose load.
Criteria for the diagnosis of diabetes include: 1. Symptoms of diabetes plus casual plasma glucose concentration 200 mg/dl (1 1.1 mmol/1).
Casual is defined as any time of day without regard to time since last meal. The classic symptoms of diabetes include polyuria, polydipsia, and unexplained weight loss; or
2. FPG 126 mg/dl (7.0 mmol/1). Fasting is defined as no caloric intake for at least 8 h; or
3. 2-h postload glucose 200 mg/dl (1 1.1 mmol/1) during an OGTT. The test should be performed as described by WHO, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.
Etiologic classification of diabetes mellitus, as embodiments, are as follows: I. Type 1 diabetes (β-cell destruction, usually leading to absolute insulin deficiency) A. Immune mediated
B. Idiopathic II. Type 2 diabetes (may range from predominantly insulin resistance with relative insulin deficiency to a predominantly secretory defect with insulin resistance) ITI. Other specific types
A. Genetic defects of β-cell function
1. Chromosome 12, 1 INF- In (MODY3)
2. Chromosome 7, glucokinase (M0DY2)
3. Chromosome 20, HNF-4Λ (MODYl)
4. Chromosome 13, insulin promoter factor- 1 (IPF- 1; MODY4)
5. Chromosome 17, FTNF-IB (MODY5)
6. Chromosome 2, NeuroDl (MODY6)
7. Mitochondrial DNA
8. Others
B. Genetic defects in insulin action
1. Type A insulin resistance
2. Leprechaunism
Rabson-Mendenhall syndrome
4. Lipoatrophic diabetes
5. Others
C. Diseases of the exocrine pancreas
1. Pancreatitis
2. Trauma/pancreatectomy
3. Neoplasia
4. Cystic fibrosis
5. Hemochromatosis
6. Fibrocalculous pancreatopathy
7. Others
D. Endocrinopathies
1. Acromegaly
2. Gushing" s syndrome
Glucagonoma
4. Pheoehromocytoma
5. Hyperthyroidism
6. Somatostalinoma
7. Aldosteronoma
8. Others
E. Drug- or chemical-induced
1. Vacor 2. Pentamidine
3. Nicotinic acid
4. Glucocorticoids
5. Thyroid hormone
6. Diazoxide 7. β-adrenergic agonists
8. Thiazides
9. Dilantin
10. α- Interferon
11. Others F. Infections
1. Congenital rubella
2. Cytomegalovirus
3. Others
G. Uncommon forms of immune-mediated diabetes 1. "Stiff-man" syndrome
2. Anti-insulin receptor antibodies
3. Others
H. Other genetic syndromes sometimes associated with diabetes
1. Down's syndrome 2. Klinefelter' s syndrome
3. Turner's syndrome
4. WoI fram ' s syndrome
5. Friedreich's ataxia
6. Iluntington's chorea 7. Laurence-Moon-Biedl syndrome
8. Myotonic dystrophy
9. Porphyria
10. Prader-Willi syndrome
1 1 . Others
IV. Gestational diabetes mellitus (GDM)
"Insulin resistance" is defined clinically as the impaired ability of a known quantity of exogenous or endogenous insulin to increase whole body glucose uptake and utilization.
"Impaired glucose tolerance (IGT)" refers to a condition known to precede the development of overt Type 2 diabetes. It is characterized by abnormal blood glucose excursions following a meal. The current criteria for the diagnosis of IGT are based on 2-h plasma glucose levels post a 75g oral glucose test (144-199 mg/dL). Although variable from population to population studied, IGT progresses to full-blown NIDDM at a rate of 1.5 to
7.3% per year, with a mean of 3-4% per year. Individuals with IGT are believed to have a 6 to 10-fold increased risk in developing Type 2 diabetes. IGT is an independent risk factor for the development of cardiovascular disease.
"'Metabolic Syndrome X" or "The Metabolic Syndrome" is characterized by a group of metabolic risk factors in one person. They include:
• Central obesity (excessive fat tissue in and around the abdomen) • Atherogenic dyslipidemia (blood fat disorders — mainly high triglycerides and low
HDL cholesterol — that foster plaque buildups in artery walls)
• Raised blood pressure (130/85 mniHg or higher)
• Insulin resistance or glucose intolerance (the body can't properly use insulin or blood sugar) • Prothrombotic state (e.g., high fibrinogen or plasminogen activator inhibitor [-1J in the blood)
• Proinflammatory state (e.g., elevated high-sensitivity C -reactive protein in the blood) According to the present invention, "Metabolic Syndrome" or "Metabolic Syndrome X" is identified by the presence of three or more of these components: • Central obesity as measured by waist circumference:
Men: Greater than 40 inches Women: Greater than 35 inches
• Fasting blood triglycerides greater than or equal to 150 mg/dL
• Blood HDL cholesterol: • Men: Less than 40 mg/dL
• Women: Less than 50 mg/dL
• Blood pressure greater than or equal to 130/85 mmllg
• Fasting glucose greater than or equal to 110 mg/dL
''Preventing" includes a slowing of the progress or development of a disease before onset or precluding onset of a disease.
'Therapeutically effective amount" means an amount of a compound or a combination of compounds that ameliorates, attenuates or eliminates one or more of the symptoms of a particular disease or condition or prevents, modifies, or delays the onset of one or more of the symptoms of a particular disease or condition.
'"Treating" or "treatment" of a disease includes a slowing of the progress or development of a disease after onset or actually reversing some or all of the disease affects. Treatment also includes palliative treatment.
"Type 1 diabetes" (formerly known as "childhood," "juvenile," "insulin-dependent" diabetes) is a form of diabetes characterized by an absolute deficiency of insulin secretion. Individuals at increased risk of developing this type of diabetes can often be identified by serological evidence of an autoimmune pathologic process occurring in the pancreatic islets and by genetic markers. Type 1 diabetes may be caused by immune mediated beta-cell destruction, usually leading to absolute insulin deficiency or may be idiopathic, having no known etiologies.
"Type 2 diabetes" refers to a heterogeneous disorder characterized by impaired insulin secretion by the pancreas and insulin resistance in tissues such as the liver, muscle and adipose tissue. The manifestations of the disease include one or more of the following: impaired glucose tolerance, fasting hyperglycemia, glycosuria, decreased levels of insulin, increased levels of glucagon, increased hepatic glucose output, reduced hepatic glucose uptake and glycogen storage, reduced whole body glucose uptake and utilization, dyslipidemia, fatty liver, ketoacidosis, microvascular diseases such as retinopathy, nephropathy and neuropathy, and macrovascular diseases such as coronary heart disease.
Description:
2-Amino-5-(2,2-dimethyl-propionyl)-4-{2-[5-(N,N'-ethoxycarbonyl-2-methylprop-2- yl) phosphonamido] furanyl}thiazole (Formula I) is a prodrug of a potent and selective inhibitor of fructose- 1,6-bisphosphatase:
(I)
Other identifying characteristics of the compound of Formula I (herein after, simply Formula I) include the following: Empirical formula: C24 H37 N4 O7 P S
Molecular mass: 556.62 g/mol
The present invention relates to polymorph Forms A-E.
In one embodiment, the invention provides for a composition consisting of, consisting essentially of or comprising Forms A.
In one embodiment, the invention provides for a composition consisting of, consisting essentially of or comprising Form B. In one embodiment, the invention provides for a composition consisting of, consisting essentially of or comprising Form C.
In one embodiment, the invention provides for a composition consisting of, consisting essentially of or comprising Form D.
In one embodiment, the invention provides for a composition consisting of. consisting essentially of or comprising Form E.
Another embodiment provides for a composition comprising Forms A and B.
Another embodiment provides for a composition comprising Forms A and C.
Another embodiment provides for a composition comprising Forms A and D.
Another embodiment provides for a composition comprising Forms A and E. Another embodiment provides for a composition comprising Forms B and C.
Another embodiment provides for a composition comprising Forms B and D.
Another embodiment provides for a composition comprising Forms B and E.
Another embodiment provides for a composition comprising Forms C and D.
Another embodiment provides for a composition comprising Forms C and E.
Another embodiment provides for a composition comprising Forms D and E.
Another embodiment provides for a composition comprising Formula I, wherein at least 50% of said Formula 1 is Form A.
Another embodiment provides for a composition comprising Formula 1. wherein at least 70% of said Formula I is Form A.
Another embodiment provides for a composition comprising Formula I, wherein at least 75% of said Formula 1 is Form A.
Another embodiment provides for a composition comprising Formula 1, wherein at least 80% of said Formula 1 is Form A. Another embodiment provides for a composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
Another embodiment provides for a composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
Another embodiment provides for a composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
Another embodiment provides for a composition comprising Formula 1, wherein at least 50% of said Formula I is Form B.
Another embodiment provides for a composition comprising Formula I, wherein at least 70%) of said Formula I is Form B. Another embodiment provides for a composition comprising Formula 1, wherein at least 75%o of said Formula I is Form B.
Another embodiment provides for a composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
Another embodiment provides for a composition comprising Formula 1, wherein at least 90% of said Formula 1 is Form B.
Another embodiment provides for a composition comprising Formula I, wherein at least 95%o of said Formula 1 is Form B.
Another embodiment provides for a composition comprising Formula I, wherein at least 98% of said Formula I is Form B. Another embodiment provides for a composition comprising Formula I, wherein at least 50%) of said Formula I is Form C.
Another embodiment provides for a composition comprising Formula I, wherein at least 70%o of said Formula I is Form C.
Another embodiment provides for a composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
Another embodiment provides for a composition comprising Formula I, wherein at least 80% of said Formula I is Form C. Another embodiment provides for a composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
Another embodiment provides for a composition comprising Formula 1, wherein at least 95% of said Formula I is Form C.
Another embodiment provides for a composition comprising Formula 1, wherein at least 98% of said Formula I is Form C.
Another embodiment provides for a composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
Another embodiment provides for a composition comprising Formula 1. wherein at least 70% of said Formula I is Form D. Another embodiment provides for a composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
Another embodiment provides for a composition comprising Formula I, wherein at least 80% of said Formula 1 is Form D.
Another embodiment provides for a composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
Another embodiment provides for a composition comprising Formula 1, wherein at least 95% of said Formula 1 is Form D.
Another embodiment provides for a composition comprising Formula I5 wherein at least 98%) of said Formula I is Form D. Another embodiment provides for a composition comprising Formula I, wherein at least 50% of said Formula 1 is Form E.
Another embodiment provides for a composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
Another embodiment provides for a composition comprising Formula 1, wherein at least 75% of said Formula I is Form E.
Another embodiment provides for a composition comprising Formula I, wherein at least 80% of said Formula 1 is Form E.
Another embodiment provides for a composition comprising Formula I, wherein at least 90% of said Formula I is Form E.
Another embodiment provides for a composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
Another embodiment provides for a composition comprising Formula I, wherein at least 98% of said Formula I is Form E. Another embodiment provides for a composition comprising Formula I, wherein said
Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula 1 is Form Λ.
Another embodiment provides for a composition comprising Formula 1, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula I is Form A.
Another embodiment provides for a composition comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula I is Form A.
Another embodiment provides for a composition comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form A.
Another embodiment provides for a composition comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula 1 is Form A. Another embodiment provides for a composition comprising Formula 1, wherein said
Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula I is Form A.
Another embodiment provides for a composition comprising Formula I. wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula 1 is Form A.
Another embodiment provides for a composition comprising Formula I. wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula I is Form A.
Another embodiment provides for a composition comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 2% of said Formula I is Form A.
Another embodiment provides for a composition comprising Formula I, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 1% of said Formula I is Form A.
Another embodiment provides for a composition comprising Formula 1, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula I is Form B.
Another embodiment provides for a composition comprising Formula T, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula I is Form B.
Another embodiment provides for a composition comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula I is Form B. Another embodiment provides for a composition comprising Formula I, wherein said
Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form B.
Another embodiment provides for a composition comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula 1 is Form B.
Another embodiment provides for a composition comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula I is Form B.
Another embodiment provides for a composition comprising Formula 1, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula I is Form B.
Another embodiment provides for a composition comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula I is Form B. Another embodiment provides for a composition comprising Formula I, wherein said
Formula I comprises at least one crystalline form selected from Forms A-E. and wherein less than 2% of said Formula I is Form B.
Another embodiment provides for a composition comprising Formula 1, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 1 % of said Formula I is Form B.
Another embodiment provides for a composition comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula I is Form C.
Another embodiment provides for a composition comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula 1 is Form C.
Another embodiment provides for a composition comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula I is Form C.
Another embodiment provides for a composition comprising Formula T, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula i is Form C. Another embodiment provides for a composition comprising Formula I. wherein said
Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula 1 is Form C.
Another embodiment provides for a composition comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula I is Form C.
Another embodiment provides for a composition comprising Formula 1, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula I is Form C.
Another embodiment provides for a composition comprising Formula 1, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula I is Form C.
Another embodiment provides for a composition comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 2% of said Formula I is Form C. Another embodiment provides for a composition comprising Formula I, wherein said
Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 1% of said Formula 1 is Form C.
Another embodiment provides for a composition comprising Formula I, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula I is Form D.
Another embodiment provides for a composition comprising Formula I, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula I is Form D.
Another embodiment provides for a composition comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula I is Form D.
Another embodiment provides for a composition comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form D.
Another embodiment provides for a composition comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula I is Form D. Another embodiment provides for a composition comprising Formula I, wherein said
Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula I is Form D.
Another embodiment provides for a composition comprising Formula 1, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula I is Form D.
Another embodiment provides for a composition comprising Formula I. wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula I is Form D.
Another embodiment provides for a composition comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 2% of said Formula I is Form D.
Another embodiment provides for a composition comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 1 % of said Formula I is Form D. Another embodiment provides for a composition comprising Formula T, wherein said
Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula I is Form E.
Another embodiment pro\ides for a composition comprising Formula I, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula I is Form E.
Another embodiment provides for a composition comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula I is Form E.
Another embodiment provides for a composition comprising Formula 1. wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form E.
Another embodiment provides for a composition comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula I is Form E.
Another embodiment provides for a composition comprising Formula I, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula I is Form E. Another embodiment provides for a composition comprising Formula I. wherein said
Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula I is Form E.
Another embodiment provides for a composition comprising Formula I, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula I is Form E.
Another embodiment provides for a composition comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 2% of said Formula I is Form E.
Another embodiment provides for a composition comprising Formula I, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 1% of said Formula I is Form E.
In another embodiment, a composition of the present invention is a pharmaceutical composition comprising Form A and a pharmaceutically acceptable excipient.
In another embodiment, a composition of the present invention is a pharmaceutical composition comprising Form B and a pharmaceutically acceptable excipient.
In another embodiment, a composition of the present invention is a pharmaceutical composition comprising Form C and a pharmaceutically acceptable excipient.
In another embodiment, a composition of the present invention is a pharmaceutical composition comprising Form D and a pharmaceutically acceptable excipient. In another embodiment, a composition of the present invention is a pharmaceutical composition comprising Form E and a pharmaceutically acceptable excipient.
Another embodiment provides for a pharmaceutical composition comprising Forms A and B and a pharmaceutically acceptable excipient.
Another embodiment provides for a pharmaceutical composition comprising Forms A and C and a pharmaceutical) y acceptable cxcipient.
Another embodiment provides for a pharmaceutical composition comprising Forms A and D and a pharmaceutically acceptable excipicnt. Another embodiment provides for a pharmaceutical composition comprising Forms A and E and a pharmaceutically acceptable excipient.
Another embodiment provides for a pharmaceutical composition comprising Forms B and C and a pharmaceutically acceptable excipient.
Another embodiment provides for a pharmaceutical composition comprising Forms B and D and a pharmaceutically acceptable excipient.
Another embodiment provides for a pharmaceutical composition comprising Forms B and E and a pharmaceutically acceptable excipient.
Another embodiment provides for a pharmaceutical composition comprising Forms C and D and a pharmaceutically acceptable excipient. Another embodiment provides for a pharmaceutical composition comprising Forms C and E and a pharmaceutically acceptable excipient.
Another embodiment provides for a pharmaceutical composition comprising Forms D and E and a pharmaceutically acceptable excipient.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 50% of said Formula I is Form A.
Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient. wherein at least 70% of said Formula I is Form A. Another embodiment provides for a pharmaceutical composition comprising Formula
I and a pharmaceutically acceptable excipient. wherein at least 75% of said Formula I is Form A.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient. wherein at least 80% of said Formula 1 is Form A.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 90% of said Formula I is Form A.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 95% of said Formula I is Form A.
Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 98% of said Formula 1 is Form A.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 50% of said Formula I is Form B. Another embodiment provides for a pharmaceutical composition comprising Formula
I and a pharmaceutically acceptable excipient, wherein at least 70% of said Formula I is Form B.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 75% of said Formula 1 is Form B.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 80% of said Formula 1 is Form B.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 90% of said Formula I is Form B.
Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 95% of said Formula I is Form B. Another embodiment provides for a pharmaceutical composition comprising Formula
1 and a pharmaceutically acceptable excipient, wherein at least 98% of said Formula 1 is Form B.
Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 50% of said Formula 1 is Form C.
Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 70% of said Formula I is Form C.
Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 75% of said Formula I is Form C.
Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 80% of said Formula I is Form C.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 90% of said Formula I is Form C. Another embodiment provides for a pharmaceutical composition comprising Formula
I and a pharmaceutically acceptable excipient, wherein at least 95% of said Formula I is Form C.
Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 98% of said Formula 1 is Form C.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 50% of said Formula I is Form D.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 70% of said Formula I is Form D.
Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 75% of said Formula 1 is Form D. Another embodiment provides for a pharmaceutical composition comprising Formula
1 and a pharmaceutically acceptable excipient, wherein at least 80% of said Formula 1 is Form D.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 90% of said Formula I is Form D.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 95% of said Formula I is Form D.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 98% of said Formula I is Form D.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 50% of said Formula 1 is Form E.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 70% of said Formula 1 is Form H. Another embodiment provides for a pharmaceutical composition comprising Formula
I and a pharmaceutically acceptable excipient, wherein at least 75% of said Formula 1 is Form E.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 80% of said Formula I is Form E.
Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein at least 90% of said Formula I is Form E.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 95% of said Formula I is Form E.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein at least 98% of said Formula I is Form E. Another embodiment provides for a pharmaceutical composition comprising Formula
1 and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E. and wherein less than 50% of said Formula I is Form A.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula 1 is Form A.
Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one
crystalline form selected from Forms A-H, and wherein less than 30% of said Formula I is Form Λ.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form A.
Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula 1 is Form A.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula 1 is Form A. Another embodiment provides for a pharmaceutical composition comprising Formula
I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula I is Form A.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula I is Form A.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 2% of said Formula I is Form A.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 1% of said Formula I is Form A.
Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula 1 is Form B.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula I is Form B. Another embodiment provides for a pharmaceutical composition comprising Formula
I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula I is Form B.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form B.
Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula I is Form B.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula 1 is Form B.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula I is Form B. Another embodiment provides for a pharmaceutical composition comprising Formula
1 and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula I is Form B.
Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 2% of said Formula I is Form B.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one
crystalline form selected from Forms A-E, and wherein less than 1% of said Formula I is Form B.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula T comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula I is
Form C.
Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient. wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula I is Form C.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula I is Form C. Another embodiment provides for a pharmaceutical composition comprising Formula
I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form C.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula I is Form C.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula I is Form C.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula I is Form C.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula 1 is Form C.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms Λ-E, and wherein less than 2% of said Formula 1 is Form C. Another embodiment provides for a pharmaceutical composition comprising Formula
I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 1% of said Formula I is Form C.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula 1 is Form D.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula I is Form D.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient. wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula 1 is Form D.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form D. Another embodiment provides for a pharmaceutical composition comprising Formula
1 and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula 1 is Form D.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula 1 is Form D.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one
crystalline form selected from Forms A-E, and wherein less than 4% of said Formula 1 is Form D.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula 1 is Form D,
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 2% of said Formula I is Form D.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 1% of said Formula I is Form D. Another embodiment provides for a pharmaceutical composition comprising Formula
I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 50% of said Formula I is Form E.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 40% of said Formula I is Form E,
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 30% of said Formula I is Form E.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 20% of said Formula I is Form E.
Another embodiment provides for a pharmaceutical composition comprising Formula 1 and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 10% of said Formula 1 is Form E.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 5% of said Formula 1 is Form E. Another embodiment provides for a pharmaceutical composition comprising Formula
I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 4% of said Formula I is Form E.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula 1 comprises at least one crystalline form selected from Forms A-E, and wherein less than 3% of said Formula 1 is Form E.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E. and wherein less than 2% of said Formula I is
Form E.
Another embodiment provides for a pharmaceutical composition comprising Formula I and a pharmaceutically acceptable excipient, wherein said Formula I comprises at least one crystalline form selected from Forms A-E, and wherein less than 1% of said Formula I is Form E.
Another embodiment provides for the use of any one or more of Forms A-E for the manufacture of a medicament for the prevention, treatment or reduction of the time to onset of a disease or clinical condition for which an FBPase inhibitor(s) is indicated.
Another embodiment provides for the use of any one or more of Forms A-E in the manufacture of a medicament for the treatment, prevention or reduction of the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels.
Another embodiment provides for a method of treating, preventing or reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of Formula I selected from Forms A-E.
Another embodiment provides for a method of for treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels,
the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides for a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels. the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B. Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D. Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E. Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A. Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form A.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogcncsis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form A.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a
pharmaceutical composition comprising Formula I, wherein at least 50% of said f ormula I is Form B.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is
Form B.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula 1 is
Form B.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is
Form B.
Another embodiment provides a method oO' treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula 1 is
Form B.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is
Form B.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is
Form B.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method
comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is
Form C,
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is
Form C.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is
Form C.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is
Form C,
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is
Form C.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is
Form C.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula T, wherein at least 99% of said Formula I is Form C.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form D.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form D.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a
pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is
Form D.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is
Form D.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is
Form D.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is
Form E.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is
Form E.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is
Form E.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method
comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula 1 is
Form E.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is
Form E.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is
Form E.
Another embodiment provides a method of treating a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is
Form E.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said
Formula I is Form A.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1. wherein at least 70% of said
Formula I is Form A.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of glυconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form Λ.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula I is Form A.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula i is Form A.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form A.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula T, wherein at least 98% of said Formula I is Form A.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 99% of said Formula I is Form A.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective
amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I5 wherein at least 70% of said
Formula I is Form B.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said
Formula I is Form B.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said
Formula 1 is Form B.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said
Formula I is Form B.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels. the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said
Formula I is Form B.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said
Formula I is Form B.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels,
the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 99% of said Formula I is Form B.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said
Formula I is Form C.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said
Formula I is Form C.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said
Formula I is Form C.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said
Formula 1 is Form C.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 90% of said
Formula 1 is Form C.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said
Formula I is Form C.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconcogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula 1 is Form C.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula 1 is Form C.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form D.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form D.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula I is Form D.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective
amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form D.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said
Formula 1 is Form D.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said
Formula I is Form D.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said
Formula 1 is Form D.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said
Formula 1 is Form E.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said
Formula I is Form E.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said
Formula 1 is Form E.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels,
the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form R.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels. the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said
Formula I is Form E.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said
Formula 1 is Form E.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 98% of said
Formula I is Form E.
Another embodiment provides a method of preventing a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said
Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least
50% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
70% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 75% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 80% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form A.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form A.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula 1 is Form A.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically
effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form B.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
70% of said Formula 1 is Form B.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
75% of said Formula 1 is Form B.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
80% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least
90% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least
95% of said Formula 1 is Form B.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least
98% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose
levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
50% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
70% of said Formula 1 is Form C.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula L wherein at least
75% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
80% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
90% of said Formula 1 is Form C.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
95% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form C.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula 1 is Form C.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 80% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically
effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
95% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least
98% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
99% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least
50% of said Formula 1 is Form E.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula i, wherein at least
70% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
75% of said Formula 1 is Form E.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose
levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
90% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
95% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
98% of said Formula 1 is Form E.
Another embodiment provides a method of reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
99% of said Formula I is Form E.
Another embodiment provides a method of treating, preventing or reducing the time to onset of Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of Formula I selected from Forms A-E.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B. Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a Form C.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D. Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form A.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A. Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 98% of said Formula 1 is Form A.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A. Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form B.
Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form B.
Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form B.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B. Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form B.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form B.
Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a
pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form C.
Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C, Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form C.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C .
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form D, Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 70% of said Formula I is Form D.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is Form D.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form D. Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form D.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a
pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula 1 is Form E.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form E.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form E. Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is Form E.
Another embodiment provides a method of treating Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form E.
Another embodiment provides a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
Another embodiment proλάdes a method of treating Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula 1 is Form E.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form A.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A. Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form A.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form A.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form A.
Another embodiment provides a method of preventing Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A. Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 99% of said Formula 1 is Form A.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeuticall) effective amount of a
pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form B.
Another embodiment provides a method of preventing Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form B.
Another embodiment provides a method of preventing Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form B.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B. Another embodiment provides a method of preventing Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form B.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula 1 is Form B.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 99% of said Formula I is Form B.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 70% of said Formula I is Form C.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form C. Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form C.
Another embodiment provides a method of preventing Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is
Form C.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C. Another embodiment provides a method of preventing Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
Another embodiment provides a method of preventing lype I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form D.
Another embodiment provides a method of preventing Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a
pharmaceutical composition comprising Formula I5 wherein at least 75% of said Formula I is Form D.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
Another embodiment provides a method of preventing fype I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I5 wherein at least 95% of said Formula I is Form D. Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form D.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form E.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I5 wherein at least 70% of said Formula I is Form E.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E. Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E,
Another embodiment provides a method of preventing 'lype I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form E.
Another embodiment provides a method of preventing Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A. Another embodiment provides a method of reducing the time to onset of Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula 1 is Form A.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula 1 is Form A.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically
effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form A. Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B. Another embodiment provides a method of reducing the time to onset of Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form B.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 99% of said Formula 1 is Form B.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form C. Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form C.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically
effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form C.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C. Another embodiment provides a method of reducing the time to onset of Type ϊ diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form D.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula i is Form D.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D. Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 99% of said Formula 1 is Form D.
Another embodiment provides a method of reducing the time to onset of Type T diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula 1 is Form E.
Another embodiment provides a method of reducing the time to onset of T>pe 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form E. Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula i is Form E.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically
effective amount of a pharmaceutical composition comprising Formula I5 wherein at least 95% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form H.
Another embodiment provides a method of reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form R.
Another embodiment provides a method of treating, preventing or reducing the time to onset of Type 11 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of Formula I selected from Forms A-E. Another embodiment provides a method of treating Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides a method of treating Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B. Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C. Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E. Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a
pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 80% of said Formula I is Form A.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A. Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form B.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B . Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is Form B.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 95% of said Formula I is Form B.
Another embodiment provides a method of treating Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B. Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
Another embodiment provides a method of treating Type 11 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a
pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula 1 is Form C.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C. Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutical!}' effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form C.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 50% of said Formula I is Form D.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 75% of said Formula I is Form D.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D. Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
Another embodiment provides a method of treating Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is
Form D.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form E. Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a
pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form E.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E.
Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
Another embodiment provides a method of treating Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wrherein at least 98% of said Formula I is Form E. Another embodiment provides a method of treating Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
Another embodiment provides a method of preventing Type 11 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
Another embodiment provides a method of preventing Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is Form A. Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering Io an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
Another embodiment provides a melhod of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form B. Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B,
Another embodiment provides a method of preventing Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a
pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is Form B.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula T, wherein at least 95% of said Formula I is
Form B.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 98% of said Formula I is Form B.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B. Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 50% of said Formula I is Form C.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form C.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
Another embodiment provides a method of preventing Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form C. Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D. Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a
pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form D.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 50% of said Formula I is Form E. Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1. wherein at least 70% of said Formula I is Form E.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 90% of said Formula I is Form E.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form E.
Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E. Another embodiment provides a method of preventing Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
70% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A. Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form Λ.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically
effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form Λ.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
99% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
Another embodiment provides a method of inducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B. Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least
90% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B. Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
75% of said Formula I is form C.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form C.
Another embodiment provides a method of reducing the time to onset of Type Il diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form C. Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically
effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 70% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D. Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 99% of said Formula 1 is Form D.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E. Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E. Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Foπn E.
Another embodiment provides a method of reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
Another embodiment provides a method of treating, preventing or reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an
animal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of Formula I selected from Forms A-E.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B. Another embodiment provides a method of preventing Metabolic Syndrome X5 the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a Form C. Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Foπn E. Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A. Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount
of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula
I is Form A.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I5 wherein at least 98% of said Formula I is Form A.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A. Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula
I is Form B.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form B.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form B. Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C. Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount
of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I5 wherein at least 99% of said Formula I is Form C.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I5 wherein at least 50% of said Formula I is Form D. Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Foπnula I, wherein at least 80% of said Formula I is Foπn D.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I. wherein at least 90% of said Formula I is Form D.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form D.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D. Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Fonnula 1 is Form D.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form E,
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Foπn E.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E. Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form E.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount
of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
Another embodiment provides a method of treating Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula
I is Form E.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A. Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form A.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A. Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula
I is Form B.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula I is Form B.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form B. Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form B.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount
of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula 1 is Form B.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula
I is Form C.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C. Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula
I is Form C.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form C.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form D. Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D. Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula 1 is Form D.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Foπnula I is Form D.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount
of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a phaπnaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E. Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a phaπnaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
Another embodiment provides a method of preventing Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form A. Another embodiment provides a method of reducing the time to onset of Metabolic
Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
90% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form A. Another embodiment provides a method of reducing the time to onset of Metabolic
Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Foπnula I, wherein at least 50% of said Foπnula I is Form B.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically
effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form B.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
75% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form B. Another embodiment provides a method of reducing the time to onset of Metabolic
Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
99% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form C.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form C.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form C. Another embodiment provides a method of reducing the time to onset of Metabolic
Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
95% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C. Another embodiment provides a method of reducing the time to onset of Metabolic
Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically
effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Foπn D.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
80% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form D.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D. Another embodiment provides a method of reducing the time to onset of Metabolic
Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 99% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
50% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form E.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E. Another embodiment provides a method of reducing the time to onset of Metabolic
Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form E.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least
98% of said Formula I is Form E,
Another embodiment provides a method of reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 99% of said Formula I is Form E.
Another embodiment provides a method of treating, preventing or reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of Formula I selected from Forms A-E. Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B. Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a phaπnaceutical composition comprising Form D.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D. Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form A.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form A. Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form A.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form A.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form A.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount
of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Foπnula I is Form B.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B. Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula
1 is Form B.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C. Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C. Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount
of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula
1 is Form D.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D. Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula
1 is Form D.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E. Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form E.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula
I is Form E.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E. Another embodiment provides a method of treating impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount
of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula
I is Form A.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A. Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B. Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form B.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form B.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B. Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form C.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form C.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount
of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Foπnula I is Form C.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C. Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula 1 is Form D.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D. Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Foπnula I is Form D.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E. Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount
of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula
I is Form E.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E. Another embodiment provides a method of preventing impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula 1 is Form E.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a phaπnaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A. Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula 1 is Form A.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form B.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a phaπnaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B. Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form B.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a
therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B. Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form C. Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula 1 is Form D.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula 1 is Form D.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form D. Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a
therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form E. Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Foπnula I, wherein at least 70% of said Formula 1 is Form E.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form E.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form E.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E. Another embodiment provides a method of reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
Another embodiment provides a method of treating, preventing or reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of Formula 1 selected from Forms A-E.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B. Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D. Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E. Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form A.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a
pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form A.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is
Form A.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form A.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form A. Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form B.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form B. Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form B.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 99% of said Formula I is Form B.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form C. Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form C.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a
pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula 1 is Form C.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C. Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D. Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form E.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E. Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula I is Form E.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a
pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
Another embodiment provides a method of treating insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E. Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Foπn A.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A. Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Foπnula I is Form A.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Foπnula I, wherein at least 99% of said Formula I is Form A.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form B.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form B.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form B. Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula I is Form B.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula 1 is Form B.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a
pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form B.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is
Form B.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form C. Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form C.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form C.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C. Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I5 wherein at least 99% of said Formula I is Form C.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form D.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form D.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula I is Form D. Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form D.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a
pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E. Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form E.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is
Form E.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
Another embodiment provides a method of preventing insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E. Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
75% of said Formula 1 is Form A.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula 1 is Form A.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form A. Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically
effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form B.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula 1 is Form B. Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C. Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form C.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
80% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form C. Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically
effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least
70% of said Formula 1 is Form D.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D. Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Foπnula I, wherein at least
98% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E. Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form E.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
90% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E. Another embodiment provides a method of reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
Another embodiment provides a method of treating, preventing or reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of Formula I selected from Forms A-E.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A. Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C. Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of Formula I selected from Forms D.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E. Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Foπnula I is Form A.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Foπnula I is Form A. Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Foπnula I is Form A.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a
pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form A.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form A.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B. Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form B.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B. Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form C.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Foπn C. Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Foπn C.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a
pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form C.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1. wherein at least 50% of said Formula I is Form D.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D. Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Foπn D.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Foπn D.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 99% of said Formula I is Form D. Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is
Form E.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E. Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Foπnula I, wherein at least 98% of said Formula I is Form E.
Another embodiment provides a method of treating hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a
pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is
Form A.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form A. Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula 1 is Form A.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form A.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form A.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B. Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is
Form B.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B. Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutical^ effective amount of a
pharmaceutical composition comprising Formula I, wherein at least 50% of said Foπnula I is Form C.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C. Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is Form C.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form C.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 99% of said Formula I is Form C.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D. Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is Form D.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form D.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula 1 is Form D. Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a
pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form E.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula I is Form E.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E. Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
Another embodiment provides a method of preventing hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Foπnula I, wherein at least 50% of said Formula 1 is Form A.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A. Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form A.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Foπn A.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A. Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a
therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B. Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C. Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D. Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a
therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form D. Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E. Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
Another embodiment provides a method of treating, preventing or reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of Formula 1 selected from Forms A-E.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A. Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C. Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D. Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A. Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form A.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form A.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a phaπnaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form A.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form A. Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form A.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount
of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Foπnula I is Form B.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula
I is Form B.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Foπnula I is Form B.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula I is Form B. Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Foπn B.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula
I is Foπn B.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 99% of said Formula T is Foπn B.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form C.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C. Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula
I is Form C.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form C.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C. Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula 1 is Form C.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount
of a pharmaceutical composition comprising Foπnula I, wherein at least 70% of said Formula I is Form D.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula
I is Form D.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form D.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D. Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula
I is Form D.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form E. Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula
I is Form E.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form E.
Another embodiment provides a method of treating accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 99% of said Formula I is Form E. Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective
amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A. Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B. Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form B.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form B.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 99% of said Formula I is Form B.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C. Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective
amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said
Formula I is Form C.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C. Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said
Formula I is Form D.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D. Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form D.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said
Formula I is Form D.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form E. Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective
amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said
Formula I is Form E.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form E.
Another embodiment provides a method of preventing accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E. Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form A.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Foπn A.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form A.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Foπnula I, wherein at least 95% of said Formula I is Form A. Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B. Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a phaπnaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a
therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Foπn B.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula 1 is Form C. Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula 1 is Form C.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula L wherein at least 90% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C. Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 75% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Foπn D. Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form D.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a
therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form D.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E. Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis. the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Foπnula I is Form E.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E. Another embodiment provides a method of treating, preventing or reducing the time to onset of increased or excessive (levels that are greater than normal for a patient having the same medical profile) hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of Formula I selected from Forms A-E. Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form A.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B. Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form B.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form C.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D. Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form D.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Form E.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form A. Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A. Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula i is Form A.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula i, wherein at least 98% of said
Formula I is Form A.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form B. Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective
amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said
Formula I is Form B.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula 1 is Form B. Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula 1 is Form B.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said
Formula 1 is Form C.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C. Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 99% of said Formula 1 is Form C,
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form D.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 70% of said Formula 1 is Form D. Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective
amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula 1 is Form D.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form D.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D. Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Foπnula I is Form E.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Foπnula I is Form E.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 95% of said Formula I is Form E. Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
Another embodiment provides a method of treating excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
50% of said Formula I is Form A.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula 1 is Form A.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula 1 is Form A. Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form A.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form A.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically
effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
98% of said Formula I is Form A.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form B. Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
80% of said Formula I is Form B.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a phaπnaceutical composition comprising Formula I, wherein at least 90% of said Formula 1 is Form B .
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B. Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
70% of said Formula I is Form C.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C. Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form C.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form C.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically
effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
99% of said Formula I is Form C.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 50% of said Formula I is Form D.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D. Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form D.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
90% of said Formula I is Form D.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form D.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D. Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least
75% of said Formula I is Form E.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form E.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form E. Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
Another embodiment provides a method of preventing excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically
effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Foπnula I, wherein at least 70% of said Formula 1 is Form A.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form A. Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form A.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula 1 is Form B. Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a phaπnaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form B. Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form B.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a
therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula I is Form C. Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Foπn C.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Foπn C.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form C.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Foπnula I, wherein at least 50% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form D. Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 80% of said Formula 1 is Form D.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 90% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 98% of said Formula I is Form D. Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula I is Form D.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 50% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a
therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 70% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 75% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 80% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula 1, wherein at least 90% of said Formula I is Form E. Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 95% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 98% of said Formula I is Form E.
Another embodiment provides a method of reducing the time to onset of excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of a pharmaceutical composition comprising Formula I, wherein at least 99% of said Formula 1 is Form E.
In one embodiment, compounds of the invention are administered in a total daily dose of 0.01 to 2500 mg. In another embodiment the range is about 1 mg to about 1000 mg. In another embodiment the range is about 1 mg to about 500 mg. In another embodiment the range is about 10 mg to about 500 mg. hi another embodiment the range is about 10 mg to about 250 mg. In another embodiment the range is about 50 mg to about 250 mg. In another embodiment the range is about 50 mg to about 150 mg. In another embodiment the range is about 50 mg to about 100 mg. In another embodiment the range is about 10 mg to about 150 mg. The dose may be administered in as many divided doses as is convenient.
One embodiment of the invention encompasses a unit dosage form which comprises a pharmaceutically acceptable composition comprising a crystalline form of the present invention and one or more pharmaceutically acceptable carrier excipients or diluents.
In another embodiment, compounds of the invention are administered in a unit dose of a range between 0.01 to 1000 mg. In another embodiment the range is about 0.1 mg to about
500 mg. In one aspect the range is about 0.1 mg to about 100 mg. In another embodiment the range is about 1 mg to about 1000 mg. In one embodiment the range is about 1 mg to about 500 mg. In another embodiment the range is about 1 mg to about 100 mg. In one embodiment the range is about 1 mg to about 10 mg. In one embodiment the range is about 10 mg to about 1000 mg. In one embodiment the range is about 10 mg to about 500 mg. In one embodiment the range is about 10 mg to about 150 mg. In one embodiment the range is about 10 mg to about 100 mg. In one embodiment, the unit dose is about 10 mg. In one embodiment, the unit dose is about 25 mg. In one embodiment, the unit dose is about 50 mg. In one embodiment, the unit dose is about 75 mg. In one embodiment, the unit dose is about 100 mg. In one embodiment, the unit dose is about 150 mg. In one embodiment, the unit dose is about 200 mg. In one embodiment, the unit dose is about 250 mg. In one embodiment, the unit dose is about 300 mg. In one embodiment, the unit dose is about 400 mg. In one embodiment, the unit dose is about 500 mg. In one embodiment, the unit dose is 600 mg. In one embodiment, the unit dose is 700 mg. In one embodiment, the unit dose is about 800 mg. In one embodiment, the unit dose is about 900 mg. In one embodiment, the unit dose is about 1000 mg.
In one embodiment the compound is administered QD (once a day). In another embodiment the compound is administered BID (twice a day). In another embodiment the compound is administered TID (three times a day). In another embodiment the compound is administered QID (four times a day). In another embodiment the compound is administered before a meal. In another embodiment the compound is administered after a meal. In another embodiment the compound is administered in the morning hours or upon awakening. In another embodiment the compound is administered in the evening hours or at bedtime.
Pharmaceutically acceptable compositions or medicaments can be administered by various means. One embodiment relates to the administration of a pharmaceutically acceptable composition of the present invention by controlled- or delayed-release means. Controlled-release pharmaceutical products have a common goal of improving drug therapy over that achieved by their non-controlled release counterparts.
A variety of known controlled- or extended-release dosage forms, formulations, and devices can be adapted for use with the crystalline forms of the invention. Examples include, but are not limited to, those described in U.S. Pat. Nos.: 3,845,770; 3,916,899; 3,536,809;
3,598, 123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5, 639,476; 5,354,556; 5,733,566; and 6,365,185; each of which is incorporated herein by reference.
These dosage forms can be used to provide slow or controlled- release of one or more active ingredients using, for example, hydroxypropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems (such as OROS, Alza Corporation, Mountain View, Calif. USA), multilayer coatings, microparticles, liposomes, or microspheres or a combination thereof to provide the desired release profile in varying proportions. Additionally, ion exchange materials can be used to prepare immobilized, adsorbed co- crystals and thus effect controlled delivery of the drug. Examples of specific anion exchangers include, but are not limited to, Duolite A568 and Duolite AP143 (Rohm & Haas, Spring House, PA, USA). One embodiment of the invention encompasses a unit dosage formulated for controlled-release which comprises a pharmaceutically acceptable composition comprising a crystalline form of the present invention and one or more pharmaceutically acceptable carrier excipients or diluents. In one embodiment the pharmaceutical composition, medicament or dosage forms is formulated for controlled-release. In another embodiment, the dosage form utilizes an osmotic drug delivery system.
A particular and well-known osmotic drag delivery system is referred to as OROS (Alza Corporation, Mountain View, Calif. USA). This technology can readily be adapted for the delivery of compounds and compositions of the invention. Various aspects of the technology are disclosed in U.S. Pat. Nos. 6, 375, 978; 6,368,626 ; 6,342,249; 6,333,050; 6,287,295; 6, 283,953; 6,270,787; 6,245,357; and 6,132,420; each of which is incorporated herein by reference.
Conventional OROS oral dosage forms are made by compressing a drug powder (e.g. a crystalline form selected from Forms A-E) into a hard tablet, coating the tablet with cellulose derivatives to form a semi-permeable membrane, and then drilling an orifice in the coating (e.g., with a laser). Kim, Cherug-ju, Controlled Release Dosage Form Design, 231- 238 (Technomic Publishing, Lancaster, PA: 2000).
A specific dosage form of the invention comprises: a wall defining a cavity, the wall having an exit orifice formed or formable therein and at least a portion of the wall being semipermeable; an expandable layer located within the cavity remote from the exit orifice
and in fluid communication with the semipermeable portion of the wall; a dry or substantially dry state drug layer located within the cavity adjacent to the exit orifice and in direct or indirect contacting relationship with the expandable layer; and a flow-promoting layer interposed between the inner surface of the wall and at least the external surface of the drug layer located within the cavity, wherein the drug layer comprises a crystalline form selected from Forms A-E. See U.S. Pat. No. 6,368,626, the entirety of which is incorporated herein by reference.
Another specific dosage form of the invention comprises: a wall defining a cavity, the wall having an exit orifice formed or formable therein and at least a portion of the wall being semipermeable; an expandable layer located within the cavity remote from the exit orifice and in fluid communication with the semipermeable portion of the wall; a drug layer located within the cavity adjacent the exit orifice and in direct or indirect contacting relationship with the expandable layer; the drag layer comprising a liquid, active agent formulation absorbed in porous particles, the porous particles being adapted to resist compaction forces sufficient to form a compacted drug layer without significant exudation of the liquid, active agent formulation, the dosage form optionally having a placebo layer between the exit orifice and the drug layer, wherein the active agent formulation comprises a crystalline form selected from Forms A-E. See U. S. Pat. No. 6,342,249, the entirety of which is incorporated herein by reference. In another embodiment, a pharmaceutical composition or medicament comprising a crystalline form selected from Forms A-E is administered transdermally. Such a transdermal (TD) delivery can avoid first-pass metabolism. Additionally, a "pill-and-patch" strategy can be taken, where only a fraction of the daily dose is delivered through the skin to generate basal systemic levels, onto which oral therapy is added. Excipients employed in pharmaceutical compositions and medicaments of the present invention can be solids, semi-solids, liquids or combinations thereof. Preferably, excipients are solids. Compositions and medicaments of the invention containing excipients can be prepared by known technique of pharmacy that comprises admixing an excipient with an API or therapeutic agent (e.g, a crystalline form selected from Forms A-E). A pharmaceutical composition or medicament of the invention contains a desired amount of a crystalline form selected from Forms A-E per dose unit and, if intended for oral administration, can be in the form, for example, of a tablet, a caplet, a pill, a hard or soft capsule, a lozenge, a cachet, a dispensable powder, granules, a suspension, an elixir, a dispersion, a liquid, or any other form reasonably adapted for such administration. If intended for parenteral administration, it can
be in the form, for example, of a solution for intravenous, intramuscular or subcutaneous injection or transdermal patch. If intended for rectal administration, it can be in the form, for example, of a suppository. Presently preferred are oral dosage forms that are discrete dose units each containing a predetermined amount of the API, such as tablets or capsules. Pharmaceutical compositions and medicaments of the invention optionally comprise one or more pharmaceutically acceptable carriers or diluents as excipients.
Suitable carriers or diluents illustratively include, but are not limited to, either individually or in combination, lactose, including anhydrous lactose and lactose monohydrate; starches, including directly compressible starch and hydrolyzed starches (e.g., Celutab and Emdex); mannitol; sorbitol; xylitol; dextrose (e.g., Cerelose 2000) and dextrose monohydrate; dibasic calcium phosphate dihydrate; sucrose-based diluents; confectioner's sugar; monobasic calcium sulfate monohydrate; calcium sulfate dihydrate; granular calcium lactate trihydrate; dextrates; inositol; hydrolyzed cereal solids; amylose; celluloses including microcrystalline cellulose, food grade sources of alpha- and amorphous cellulose (e.g., RexcelJ), powdered cellulose, hydroxypropylcellulose (HPC) and hydroxypropylmethylcellulose (HPMC); calcium carbonate; glycine; bentonite; block copolymers; polyvinylpyrrolidone; and the like. Such carriers or diluents, if present, constitute in total about 5% to about 99%, preferably about 10% to about 85%, and more preferably about 20% to about 80%, of the total weight of the composition. The carrier, carriers, diluent, or diluents selected preferably exhibit suitable flow properties and, where tablets are desired, compressibility.
Lactose, mannitol, dibasic sodium phosphate, and microcrystalline cellulose (particularly Avicel PH microcrystalline cellulose such as Avicel PH 101), either individually or in combination, are examples of diluents. These diluents are chemically compatible with APIs. The use of extragranular microcrystalline cellulose (that is, microcrystalline cellulose added to a granulated composition) can be used to improve hardness (for tablets) and/or disintegration time. Lactose, especially lactose monohydrate, is particularly preferred. Lactose typically provides compositions having suitable release rates of APIs, stability, pre- compression flowability, and/or drying properties at a relatively low diluent cost. It provides a high density substrate that aids densifϊcation during granulation (where wet granulation is employed) and therefore improves blend flow properties and tablet properties.
Pharmaceutical compositions and medicaments of the invention optionally comprise one or more pharmaceutically acceptable disintegrants as excipients, particularly for tablet formulations. Suitable disintegrants include, but are not limited to, either individually or in
combination, starches, including sodium starch glycolate (e.g., Explotab of Pen West) and pregelatinized corn starches (e.g., National 1551 of National Starch and Chemical Company, National 1550, and Colocorn 1500), clays (e.g., Veegum HV of R.T. Vanderbilt), celluloses such as purified cellulose, micro crystalline cellulose, methylcellulose, carboxymethylcellulose and sodium carboxymethylcellulose, croscarmellose sodium (e.g.,
Ac-Di-SoI of FMC), alginates, crospovidone, and gums such as agar, guar, locust bean, karaya, pectin and tragacanth gums.
Disintegrants may be added at any suitable step during the preparation of the composition, particularly prior to granulation or during a lubrication step prior to compression. Such disintegrants, if present, constitute in total about 0.2% to about 30%, preferably about 0. 2% to about 10%, and more preferably about 0.2% to about 5%, of the total weight of the composition.
Croscarmellose sodium is a preferred disintegrant for tablet or capsule disintegration, and, if present, preferably constitutes about 0.2% to about 10%, more preferably about 0.2% to about 7%, and still more preferably about 0.2% to about 5%, of the total weight of the composition. Croscarmellose sodium confers superior intragranular disintegration capabilities to granulated pharmaceutical compositions and medicaments of the present invention.
Pharmaceutical compositions and medicaments of the invention optionally comprise one or more pharmaceutically acceptable binding agents or adhesives as excipients, particularly for tablet formulations. Such binding agents and adhesives preferably impart sufficient cohesion to the powder being tableted to allow for normal processing operations such as sizing, lubrication, compression and packaging, but still allow the tablet to disintegrate and the composition to be absorbed upon ingestion. Such binding agents may also prevent or inhibit crystallization or recrystallization of an API of the present invention once the compound has been dissolved in a solution. Suitable binding agents and adhesives include, but are not limited to, either individually or in combination, acacia; tragacanth; sucrose; gelatin; glucose; starches such as, but not limited to, pregelatinized starches (e.g., National 1511 and National 1500); celluloses such as, but not limited to, methylcellulose and carmellose sodium (e.g., Tylose); alginic acid and salts of alginic acid; magnesium aluminum silicate; PEG; guar gum; polysaccharide acids; bentonites; povidone, for example povidone K-15, K-30 and K-29/32; polymethacrylates; HPMC; hydroxypropylcellulose (e.g., Klucel of Aqualon), and ethylcellulose (e. g., Ethocel of the Dow Chemical Company). Such binding agents and/or adhesives, if present, constitute in total about 0.5% to about 25%, preferably
about 0.75% to about 15%, and more preferably about 1% to about 10%, of the total weight of the pharmaceutical composition or medicament.
Many of the binding agents are polymers comprising amide, ester, ether, alcohol or ketone groups and, as such, are preferably included in pharmaceutical compositions and medicaments of the present invention. Polyvinylpyrrolidones such as povidone K-30 are especially preferred. Polymeric binding agents can have varying molecular weight, degrees of crosslinking, and grades of polymer. Polymeric binding agents can also be copolymers, such as block co-polymers that contain mixtures of ethylene oxide and propylene oxide units. Variation in these units' ratios in a given polymer affects properties and performance. Examples of block co- polymers with varying compositions of block units are Poloxamer 188 and Poloxamer 237 (BASE Corporation).
Pharmaceutical compositions and medicaments of the invention optionally comprise one or more pharmaceutically acceptable wetting agents as excipients. Such wetting agents are preferably selected to maintain the API in close association with water, a condition that is believed to improve bioavailability of the composition.
Non-limiting examples of surfactants that can be used as wetting agents in pharmaceutical compositions and medicaments of the invention include quaternary ammonium compounds, for example benzalkonium chloride, benzethonium chloride and cctylpyridinium chloride, dioctyl sodium sulfosuccinate, polyoxyethylene alkylphenyl ethers, for example nonoxynol 9, nonoxynol 10, and octoxynol 9, poloxamers (polyoxyethylene and polyoxypropylene block copolymers), polyoxyethylene fatty acid glycerides and oils, for example polyoxyethylene (8) caprylic/capric mono- and diglycerides (e.g., Labrasol^ of Gattefosse), polyoxyethylene (35) castor oil and polyoxyethylene (40) hydrogenated castor oil; polyoxyethylene alkyl ethers, for example polyoxyethylene (20) cetostearyl ether, polyoxyethylene fatty acid esters, for example polyoxyethylene (40) stearate, polyoxyethylene sorbitan esters, for example polysorbate 20 and polysorbate 80 (e.g., Tween 80 of ICI), propylene glycol fatty acid esters, for example propylene glycol laurate (e.g., Lauroglycol of Gattefosse), sodium lauryl sulfate, fatty acids and salts thereof, for example oleic acid, sodium oleate and triethanolamine oleate, glyceryl fatty acid esters, for example glyceryl monostearate, sorbitan esters, for example sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate and sorbitan monostearate, tyloxapol, and mixtures thereof. Such wetting agents, if present, normally constitute in total about 0.25% to about 15%, preferably about 0.4% to about 10%, and more preferably about 0.5% to about 5%, of the total weight of the pharmaceutical composition or medicament.
Wetting agents that are anionic surfactants are preferred. Sodium lauryl sulfate is a particularly preferred wetting agent. Sodium lauryl sulfate, if present, normally constitutes about 0.25% to about 7%, more preferably about 0. 4% to about 4%, and still more preferably about 0.5% to about 2%, of the total weight of the pharmaceutical composition or medicament.
Pharmaceutical compositions and medicaments of the invention optionally comprise one or more pharmaceutically acceptable lubricants (including anti-adherents and/or glidants) as excipients. Suitable lubricants include, but are not limited to, either individually or in combination, glyceryl behapate (e.g., Compritol 888 of Gattefosse); stearic acid and salts thereof, including magnesium, calcium and sodium stearates; hydrogenated vegetable oils (e.g., Sterotex of Abitec); colloidal silica; talc; waxes; boric acid; sodium benzoate; sodium acetate; sodium fumarate; sodium chloride; DL-leucine; PEG (e.g., Carbowax 4000 and Carbowax 6000 of the Dow Chemical Company); sodium oleate; sodium lauryl sulfate; and magnesium lauryl sulfate. Such lubricants, if present, normally constitute in total about 0. 1% to about 10%, preferably about 0.2% to about 8%, and more preferably about 0.25% to about
5%, of the total weight of the pharmaceutical composition or medicament. Magnesium stearate is a preferred lubricant used, for example, to reduce friction between the equipment and granulated mixture during compression of tablet formulations.
Suitable anti-adherents include, but are not limited to, talc, cornstarch, DL- leucine, sodium lauryl sulfate and metallic stearates. Talc is a preferred anti-adherent or glidant used, for example, to reduce formulation sticking to equipment surfaces and also to reduce static in the blend. Talc, if present, constitutes about 0.1% to about 10%, more preferably about 0.25% to about 5%, and still more preferably about 0.5% to about 2%, of the total weight of the pharmaceutical composition or medicament. Glidants can be used to promote powder flow of a solid formulation. Suitable glidants include, but are not limited to, colloidal silicon dioxide, starch, talc, tribasic calcium phosphate, powdered cellulose and magnesium trisilicate. Colloidal silicon dioxide is particularly preferred.
Other excipients such as colorants, flavors and sweeteners are known in the pharmaceutical art and can be used in pharmaceutical compositions and medicaments of the present invention. Tablets can be coated, for example with an enteric coating, or uncoated. Compositions of the invention can further comprise, for example, buffering agents.
Optionally, one or more effervescent agents can be used as disintegrants and/or to enhance organoleptic properties of pharmaceutical compositions and medicaments of the invention. When present in pharmaceutical compositions and medicaments of the invention to
promote dosage form disintegration, one or more effervescent agents are preferably present in a total amount of about 30% to about 75%, and preferably about 45% to about 70%, for example about 60%, by weight of the pharmaceutical composition or medicament.
According to a particularly preferred embodiment of the invention, an effervescent agent, present in a solid dosage form in an amount less than that effective to promote disintegration of the dosage form, provides improved dispersion of the API in an aqueous medium. Without being bound by theory, it is believed that the effervescent agent is effective to accelerate dispersion of the API, from the dosage Forms A-En the gastrointestinal tract, thereby further enhancing absorption and rapid onset of therapeutic effect. When present in a pharmaceutical composition or medicament of the invention to promote intragastrointestinal dispersion but not to enhance disintegration, an effervescent agent is preferably present in an amount of about 1% to about 20%, more preferably about 2.5% to about 15%, and still more preferably about 5% to about 10%, by weight of the pharmaceutical composition or medicament. An "effervescent agent" herein is an agent comprising one or more compounds which, acting together or individually, evolve a gas on contact with water. The gas evolved is generally oxygen or, most commonly, carbon dioxide. Preferred effervescent agents comprise an acid and a base that react in the presence of water to generate carbon dioxide gas. Preferably, the base comprises an alkali metal or alkaline earth metal carbonate or bicarbonate and the acid comprises an aliphatic carboxylic acid.
Non-limiting examples of suitable bases as components of effervescent agents useful in the invention include carbonate salts (e.g., calcium carbonate), bicarbonate salts (e.g., sodium bicarbonate), sesquicarbonate salts, and mixtures thereof. Calcium carbonate is a preferred base. Non-limiting examples of suitable acids as components of effervescent agents and/or solid acids useful in the invention include citric acid, tartaric acid (as D-, L-, or D/L-tartaric acid), malic acid, maleic acid, fumaric acid, adipic acid, succinic acid, acid anhydrides of such acids, acid salts of such acids, and mixtures thereof. Citric acid is a preferred acid.
In a preferred embodiment of the invention, where the effervescent agent comprises an acid and a base, the weight ratio of the acid to the base is about 1 : 100 to about 100:1, more preferably about 1:50 to about 50:1, and still more preferably about 1 :10 to about 10:1. In a further preferred embodiment of the invention, where the effervescent agent comprises an acid and a base, the ratio of the acid to the base is approximately stoichiometric.
Excipients which solubilize salts of APIs may have both hydrophilic and hydrophobic regions, or are preferably amphiphilic or have amphiphilic regions. One type of amphiphilic or partially- amphiphilic excipient comprises an amphiphilic polymer or is an amphiphilic polymer. A specific amphiphilic polymer is a polyalkylene glycol, which is commonly comprised of ethylene glycol and/or propylene glycol subunits. Such polyalkylene glycols can be esterified at their termini by a carboxylic acid, ester, acid anhyride or other suitable moiety. Examples of such excipients include poloxamers (symmetric block copolymers of ethylene glycol and propylene glycol; e.g., poloxamer 237), polyalkyene glycolated esters of tocopherol (including esters formed from a di- or multi-functional carboxylic acid; e.g., d- alpha-tocopherol polyethylene glycol- 1000 succinate), and macrogolglycerides (formed by alcoholysis of an oil and esterification of a polyalkylene glycol to produce a mixture of mono-, di- and tri-glycerides and mono- and all- esters; e.g., stearoyl macrogol-32 glycerides). Such pharmaceutical compositions and medicaments are advantageously administered orally. Solid dosage forms of the invention can be prepared by any suitable process, not limited to processes described herein. An illustrative process comprises (a) a step of blending a compound of the invention with one or more excipients to form a blend, and (b) a step of tableting or encapsulating the blend to form tablets or capsules, respectively.
In a preferred process, solid dosage forms are prepared by a process comprising (a) a step of blending a compound of the invention with one or more excipients to form a blend, (b) a step of granulating the blend to form a granulate, and (c) a step of tableting or encapsulating the blend to form tablets or capsules respectively. Step (b) can be accomplished by any dry or wet granulation technique known in the art, but is preferably a dry granulation step. A compound of the present invention is advantageously granulated to form particles of about 1 micrometer to about 100 micrometer, about 5 micrometer to about 50 micrometer, or about 10 micrometer to about 25 micrometer. One or more diluents, one or more disintegrants and one or more binding agents are preferably added, for example in the blending step, a wetting agent can optionally be added, for example in the granulating step, and one or more disintegrants are preferably added after granulating but before tableting or encapsulating. A lubricant is preferably added before tableting. Blending and granulating can be performed independently under low or high shear. A process is preferably selected that forms a granulate that is uniForms A-En API content, that readily disintegrates, that flows with sufficient ease so that weight variation can be reliably controlled during capsule filling or
tableting, and that is dense enough in bulk so that a batch can be processed in the selected equipment and individual doses fit into the specified capsules or tablet dies.
In an alternative embodiment, solid dosage forms are prepared by a process that includes a spray drying step, wherein the API is suspended with one or more excipients in one or more sprayable liquids, preferably a non-protic (e.g., non-aqueous or non-alcoholic) sprayable liquid, and then is rapidly spray dried over a current of warm air.
A granulate or spray dried powder resulting from any of the above illustrative processes can be compressed or molded to prepare tablets or encapsulated to prepare capsules. Conventional tableting and encapsulation techniques known in the art can be employed. Where coated tablets are desired, conventional coating techniques are suitable.
Excipients for tablet compositions of the invention are preferably selected to provide a disintegration time of less than about 30 minutes, preferably about 25 minutes or less, more preferably about 20 minutes or less, and still more preferably about 15 minutes or less, in a standard disintegration assay. In another embodiment the invention provides for a pharmaceutical composition or medicament comprising a first API that is a crystalline form selected from Forms A-E and a second API, wherein said first API and second API are not the same API.
EXAMPLES
Chemical synthesis of compound
Preparation of 2-amino-5-(2,2-dimethylpropionyl)-4- {[5-(N,N'-(2-ethoxy- carbonylprop-2-yl)phosphonamido]furan-2-yl}thiazole:
Step A
A solution of 2-furoic acid (1 mmole) in THF was added to a THF solution of LDA (lithium diisopropylamide, 2 mmole) at -78 0C and the resulting solution was stirred at - 78 0C. After Ih the reaction mixture was treated with diethyl chlorophosphate (1.2 mmole), stirred at - 78 0C for 1 h and at 25 0C for 12 h. The reaction mixture was quenched with saturated ammonium chloride. Extraction and chromatography gave 5-diethylphosphono-2-furoic acid as a yellow solid.
Step B
A solution of 5-diethylphosphono-2-furoic acid (1 mmole) and O-m ethyl -N-methylhydroxylamide HCl salt (1.3 mmole) in DMF was treated with triethylamine (2.2 mmole) and benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP, 1.2 mmole) at 25 0C. After 12 h, the reaction was subject to extraction and chromatography to give 5-diethylphosphono-
2-(N-methyl-N-methoxy)furancarboxamide as a solid.
Step C
A solution of pinacolone (1.4 mmole) in THF was cooled to -78 0C and treated with n-BuLi (1.5 mmole). After 1 h, to the reaction was added a solution of 5-diethylphosphono-2-(N-methyl-N-methoxy)furancarboxamide (1 mmole) in THF and stirred at -78 0C for 1 h and at 25 0C for 12 h. The reaction was quenched with saturated ammonium chloride and subjected to extraction and chromatography to give 5-diethylphosphono-2-[l-(4,4-dimethyl-l,3-dioxo)pentyl]furan as an oil.
Step D
A solution of 5-diethylphosphono-2-[l-(4,4-dimethyl-l,3-dioxo)pentyl]furan (1 mmole) in carbon tetrachloride and ethanol was treated with copper (II) bromide (1.6 mmole) at 25 0C. After heating at 70 0C for 3 h the reaction was cooled to 25 0C and subjected to extraction and chromatography to give 5-diethylphosphono-2-[l-(2-bromo-4,4-dimethyl-l ,3- dioxo)pentyl]furan as an oil.
Step E
A solution of 5-diethylphosphono-2-[l-(2-bromo-4,4-dimethyl-l ,3-dioxo)- pentyljfuran (1 mmole) in ethyl acetate and ethanol was treated with thiourea (1.8 mmole) at 25 0C. After heating at 70 0C for 3 h the reaction was cooled to 25 0C and subjected to extraction and chromatography to give
{5-[2-Amino-5-(2,2-dimethyl-propionyl)-thiazol-4-yl]-furan-2-yl}-phosphonic acid diethyl ester as a solid.
Step F
A solution of {5-[2-amino-5-(2,2-dimethyl-propionyl)thiazol- 4-yl]furan-2-yl}phosphonic acid diethyl ester (1 mmole) in methylene chloride was treated
with TMSBr (10 mmole) at 25 0C. After 12 h the reaction was evaporated to dryness and the residue was suspended in acetone-water to give a yellow solid. The solid was collected via filtration and dried under vacuum to give {5-[2-amino-5-(2,2-dimethyl-propionyl)thiazol- 4-y]]-furan-2-yl}phosphonic acid (Formula II) as a solid. Mp > 220 0C. Anal, calcd. for Ci2H15N2O5PS: C: 43.64; H: 4.58; N: 8.48. Found: C: 43.47; H: 4.64: N: 8.55.
(H)
Step G.
A solution of {5-[2-amino-5-(2,2-dimethyl-propionyl)thiazol-4-yl]furan-2-yl}phosphonic acid (1 mmole), DMF (1.2 mmole) and oxalyl chloride (4 mmole) in 1 ,2-dichloroeιhane was heated at 50 0C for 2 h. The reaction solution was evaporated to dryness and the residue was redissolved in 1,2-dichloroethane. After cooling to O0C, 2-methylalanine ethyl ester (3.5 mmole) and N,N-diethylisopropylamine (3.5 mmole) were added. After stirring at 25 0C for
12 h, the reaction was subjected to extraction and chromatography to give
2-(dimethylaminomethyleneamino)-5-(2,2- dimethylpropionyl)-4-{2-[5-(N,N'-2-ethoxycarbonylprop-2-yl)-phosphon-amido]- furanyl}thiazole.
Step H.
A solution of 2-(dimethylamino-methyleneamino)-5-(2,2- dimethylpropionyl)-4-{[5-(N,N'-2-ethoxycarbonylprop-2-yl)phosphonamido]furan-2- yl}thiazole (1 mmole) in acetic acid and isopropanol was heated to 85 0C. After 12h the reaction was subjected to extraction and chromatography to give 2-amino-5-(2,2- dimethylpropionyl)-4- { [ 5 - (N,N ' - (2- ethoxy- carbonylprop-2-yl)phosphonamido]furan-2-yl}thiazole (Formula I) as a yellow solid. Anal.
CaICcI fOr C24H37N4O7PS: C: 51.79; H: 6.70; N: 10.07. Found: C: 51.39; H: 6.51; N: 10.26.
(I)
O Il H-P(OEt)2
[(C6H5J3P]4Pd
Scheme 1
Formula I can also be prepared by the synthetic scheme shown in Scheme 1. 5-Bromo-2- furoic acid is converted to the acid chloride 1 with oxalyl chloride or other suitable reagents. The acid chloride 1 is condensed with the anion of pinacolone to form diketone 2. The bromofuran diketone 2 is phosphonylated with diethyl phosphate to diketone 3 using a suitable transition metal catalyst such as tetrakis(triphenylphosphine)palladium (0). The diketone 3 is halogenated with a suitable reagent such as bromine or sulfuryl chloride to
provide halodiketone 4. The dialkylphosphonate is condensed with thiourea to provide thiazole 5. The dialkylphosphonate functionality of 5 is deprotected using a suitable reagent such as trimethylsilyl halide to provide the phosphonic acid 6. The phosphonic acid 6 is converted to an amidine protected phosphonodichloridate using sutable reagents such as oxalyl chloride with a dialkylformamide, or thionyl chloride. The phosphonodichloridate is treated with 2-methyl alanine ethyl ester hydrochloride or the free base, and a suitable acid- scavenging base such as triethylamine or diisopropylethylamine (DIPEA), to provide the crude bisamidate. The arnidine protecting group is removed with a suitable reagent such as acetic acid in ethanol to form the product Formula I.
Analytical Methods
Unless specifically set forth in an Example to the contrary, analytical methods were carried out as follows. See Examples for specific analytical methods used to characterize a specific form. X -ray powder diffraction (XRPD) analysis was performed using a Shimadzu XRD-
6000 X-Ray powder diffractometer using Cu Ka radiation. The instrument is equipped with a fine focus X-ray tube. The tube voltage and amperage were set to 4OkV and 4OmA, respectively. The divergence and scattering slits were set at 1° and the receiving slit was set at 0.15 mm. Diffraction radiation was detected by NaI scintillation detector. A theta - two theta continuous scan at 3° / minute (0.4 second / 0.02° step) from 2.4 to 40° 2Θ was used. A silicon standard was analyzed to check the instrument alignment. Data were collected and analyzed using XRD / 6000 v.4.1.
X-ray powder diffraction (XRPD) analyses were also performed using an Inel XRG- 3000 diffractometer equipped with a CPS (Curved Position Sensitive) detector with a 20 range of 120°. Real time data were collected using a Cu-Ka radiation starting at approximately 4 ° 20 at a resolution of 0.03 ° 2Θ. The tube voltage and amperage were set to 40 kV and 30 mA, respectively. The monochromator slit was set at 5 mm by 160μm. The pattern is displayed from 2.5-40 ° 2Θ. Samples were prepared for analysis by packing them into thin-walled glass capillaries. Each capillary was mounted onto a goniometer head that is motorized to permit spinning of the capillary during data acquisition. The samples were analyzed for 2 min. Instrument calibration was performed using a silicon reference standard. The experimental XRPF pattern was collected at SSCI, Inc. using the as-received sample according to cGMP specifications.
Variable-temperature XRPD (VT-XRPD) was performed on a Shimadzu XRD-6000 X-ray powder diffractometer equipped with an Anton Paar HTK 1200 high temperature stage. The sample was packed in a ceramic holder and analyzed from 2.5 to 40° 2Θ at 3 7min (0.4sec/0/02° step). A silicon standard was analyzed to check the instrument alignment. Differential scanning calorimetery (DSC) was performed using a TA instrument differential scanning calorimeter 2920. Each sample was placed into an aluminum DSC pan, and the weight accurately recorded. The pan was then covered with a lid. Each sample was equilibrated at 25 0C and heated under a nitrogen purge at a rate of 100C / minute, upto a final temperature of 350 0C. Indium metal was used as the calibration standard. Reported temperatures are at the transition maxima.
Cyclic differential scanning calorimetry (Cyclic DSC) was performed using a TA Instruments 2920 differential scanning calorimeter. The sample was placted into an aluminum DSC pan and the weight accurately recorded. The pan was covered with a lid and then crimped. The method was as follows: 1. Equilibrate at 25.00 0C,
2. Ramp 5 oC/min to 175 0C,
3. Isothermal at 175 0C for 5 min,
4. Equilibrate at 25 0C,
5. Ramp 5 °C/min to 225 0C. Indium metal was used as the calibration standard. Reported temperature is at the transition maxima.
Thermogravimetric (TG) analyses were performed using a TA instruments 2050 thermogravemetric analyzer. The sample was placed in an aluminum sample pan, into the TG furnace. The sample was first equilibrated at 250C, than heated under nitrogen at 100C / min, up to a final temperature of 350 0C. Nickel and ALUMEL™ were used as the calibration standards.
Hot-stage microscopy was peformed using a Linkman hot-stage (model FTIR 600) mounted on a Leica DM microscope. Samples were observed using a 2Ox objective with a lambda place and crossed polarizers. Samples were placed on a coverslip. Another coverslip was then placed over the sample. Each sample was visually observe as the stage was heated.
The hot-stage was calibrated using USP melting point standards.
Moisture sorption / desorption data were collected on a VTI SGA/100 Vapor Sorption Analyzer using VTI Flow System Software / Step Isotherm Experiment. Sorption and
Desorption data were collected over a range of 5% to 95% relative humidity (RH) at 10% RH intervals under a nitrogen purge. Samples were not dried prior to analysis. Equilibrium criteria used for analysis was less than 0.0100% weight change in 5 minutes, with a maximum equilibration time of 3 hours if the weight criterion was not met. Data were not collected for the initial moisture content of the samples. NaCl and PVP were used as calibration standards.
Optical microscopy was performed using a Wolfe Microscope. Samples were observed at magnification of 40x using cross-polarizers.
Example 1. Form A:
Crystalline Form A was made by adding tetrahyrofuran (THF) to 2-Amino-5-(2,2- dimethyl-propionyl)-4-{2-[5-(N,N'-ethoxycarbonyl-2-methylprop-2-yl) phosphonamido] furanyl}thiazole [1.5:1 (vol:wt) THF:Formula I]. The solution (about 20 0C) was stirred and ambient temperature n-heptane was added rapidly [5:1 (vol:wt) heptane: Formula I]. The filter cake was washed with n-heptane and dried in a vacuum oven at 40 0C.
A representative XRPD pattern (Shimadzu XRD-6000) of Form A is shown in Figure 1. The peaks in the list below are selected from XRPD images that represent clear signals above the noise level. Peak positions can be +/- 0.2 °2theta.
*weak signals.
TG analysis of Form A sample demonstrated an insignificant weight loss indicating the solid is anhydrous and unsolvated (Figure II). DSC data revealed a single major endothermic transition with a peak maximum at about 156 0C and a minor endothermic transition at about 170 0C (Figure T), Hot-stage microscopy analysis showed a melt at about 154 0C, followed by a recrystallization and a second melt of the recrystallazation phase at about 169 0C.
Automated moisture sorption/desorption analysis of Form A sample exhibited insignificant weight gain of 0.22% at 95% RH. Upon desorption to 5% RH, the sample returned to its initial mass.
Example 2. Form B:
Crystalline Form B was made by adding methanol (can also be made with ethanol) to 2-Amino-5-(2,2-dimethyl-propionyl)-4- (2-[5-(N,N'-ethoxycarbonyl-2-methylprop-2-yl) phosphonamido] furanyljthiazole [4:1 (vol:wt), methanol: Formula I] and heating the solution to 50 0C. The heating source was turned off and water was added [2:1 (vol:wt), wateπFormula I]. The solution was allowed to cool to ambient temperature and then stirred again at ambient temperature. The mixture was then cooled to 3 0C. The mixture was filtered and the filter cake washed with 2:1 (vol:vol) methanol:water and dried.
A representative XRPD pattern (Inel XRG-3000) of Form B is shown in Figure 3. The peaks in the list below are selected from XRPD images that represent clear signals above the noise level. Peak positions can be +/- 0.2 °2theta.
* Weak signals
Form B material is non-hygroscopic, anhydrous, crystalline solid with a melting point at approximately 156-162 0C, as determined by DSC and hot-stage microscopy. The single 5 crystal structure of Form B was also determined. A calculated XRPD from the single crystal data is shown in Figure 4.
Single crystals of Form B were generated through the slow evaporation of an acetone/water 2:1 solution.
A colorless needle Of C24H37N4O7PS having approximate dimensions of 0.48 x 0.15 x
10 0.10 mm, was mounted on a glass fiber in random orientation. Preliminary examination and data collection were performed with Mo Ka radiation (λ = 0.71073 A) on a Nonius KappaCCD diffractometer. Refinements were performed on an LINUX PC using SHELX97 [Sheldrick, G.M. Shelx97, A Program for Crystal Structure Refinement, University of Gottingen, Germany, 1997].
] 5 Cell constants and an orientation matrix for data collection were obtained from least- squares refinement using the setting angles of 43922 reflections in the range of 2° < θ < 25°. The refined mosaicity from DENZO/SCALEPACK [Otwinowski, Z, Minor, W. Methods En∑ymol. 1997, 276, 307] was 0.30° indicating good crystal quality. The space group was determined by the program ABSEN [McArdle, P.C. J. Appl. Cryst. 1996, 29, 306]. From the
20 systematic presence oϊhOl l=2n and OkO k=2n, and from subsequent least-squares refinement, the space group was determined to be P2;/c (no. 14). The data were collected to a maximum 2 θ value of 51.4°, at a temperature of 150 ± 1 K.
A total of 43922 reflections were collected, of which 10791 were unique. Lorentz and polarization corrections were applied to the data. The linear absorption coefficient is 2.0 cm"1
25 for Mo Ka radiation. An empirical absorption correction using SCALEPACK [Otwinowski,
Z, Minor, W. Methods En∑ymol. 1997, 276, 307] was applied. Transmission coefficients ranged from 0.939 to 0.980. Intensities of equivalent reflections were averaged. The agreement factor for the averaging was 9.9% based on intensity.
The structure was solved by direct methods using PATTY in DIRDIF99 [Beurskens, P.T.; Beurskens, G.; deGelder, R.; Garcia-Granda, S.; Gould, R.O.; Israel, R.; Smits, J.M. M.
The DIRDIF-99 Program System Crystallography Laboratory, Univ. of Nijmegen, The
Netherlands, (1999)]. The remaining atoms were located in succeeding difference Fourier syntheses. Hydrogen atoms were included in the refinement but restrained to ride on the atom to which they are bonded. The structure was refined in full-matrix least-squares by minimizing the function:
Σ4F-\ -\F<
The weight w is defined as \l[cf{F0 2) + (0.0664Ff +(0.0000P)], where P = (F0 2 +2Fc 2)/3.
Scattering factors were taken from the "International Tables for Crystallography" [International Tables for Crystallography, Vol. C, Kluwer Academic Publishers; Dordrecht, The Netherlands, 1992, Tables 4.2.6.8 and 6.1.1.4]. Of the 10066 reflections used in the refinements, only the reflections with F0" > 2σ(F0") were used in calculating R. A total of 5428 reflections were used in the calculation. The final cycle of refinement included 717 variable parameters and converged (largest parameter shift was < 0.01 times its estimated standard deviation) with unweighted and weighted agreement factors of:
Λ = ∑ |^o -^c|/∑^o =0.048
The standard deviation of an observation of unit weight was 0.93. The highest peak in the final difference Fourier had a height of 0.44 e/A . The minimum negative peak had a height of - 0.39 e/A3. A calculated XRPD pattern was generated for Cu radiation using Mercury v 1.2.1 and the atomic coordinates, space group, and unit cell parameters from the single crystal data.
X-ray powder diffraction (XRPD) analyses were performed using an Inel XRG-3000 diffractometer equipped with a CPS (Curved Position Sensitive) detector with a 2Θ range of 120°. Real time data were collected using Cu-Ka radiation starting at approximately 4 °2Θ at a resolution of 0.03 °2Θ. The tube voltage and amperage were set to 40 kV and 30 mA, respectively. The monochromator slit was set at 5 mm by 160 μm. The pattern is displayed from 2.5-40 °2Θ. Samples were prepared for analysis by packing them into thin-walled glass capillaries. Each capillary was mounted onto a goniometer head that is motorized to permit spinning of the capillary during data acquisition. The samples were analyzed for 2 min. Instrument calibration was performed using a silicon reference standard. The monoclinic cell parameters and calculated volume are: a = 1 1.4905(4), b =
16.3218(10), c = 30.8664(17) A, a = 90.00,^ = 93.393(3), γ = 90.00°, F= 5778.7(5) A3. For Z = S and formula weight of 556.62 the calculated density is 1.28 g cm"3. The space group was determined to be P2j/c (no. 14). The crystallographic data and data collection parameters are provided in Table 1. Differences in intensities between the experimental and calculated patterns are likely due to preferred orientation. Preferred orientation is the tendency for crystals, usually plates or needles, to align themselves with some degree of order. Preferred orientation can affect peak intensities, but not peak positions, in XRPD patterns. The slight shifts in peak location are likely due to the fact that the experimental powder pattern was collected at ambient temperature, and the single crystal data was collected at 150 K. Low temperatures are used in single crystal analysis to improve the quality of the structure.
Table 1. Crystallographic Data and Data Collection Parameters for Form B formula C24H37N4O7PS formula weight 556.62 space group Pl1Ic (No. 14) a, A 11.4905(4) b, λ 16.3218(10) c, λ 30.8664(17) β, deg 93.393(3) v, A3 5778.7(5)
Z 8 dcaic, g cm"3 1.280 crystal dimensions, mm 0.48x0.15x0.10 temperature, K 150. radiation (wavelength, A ) Mo Kx (0.71073) monochromator graphite linear abs coef, mm"1 0.205 absorption correction applied emρiricala transmission factors: min, max 0.94, 0.98 diffractometer Nonius KappaCCD h, k, I range O to 14 O to 19 -37 to 37
2Θ range, deg 4.30°-51.41° mosaicity, deg 0.30 programs used SHELXTL
•Pooo 2368.0 weighting ϊ /[s 2CF0 2HO.0664P)2+0.000(IP] where P=( FO 2+2FC 2)B data collected 43922 unique data 10791
0.099 data used in refinement 10066 cutoff used in i?-factor calculations Fo 2>2.0sCFo 2) data with I>2. Os (T) 5428 number of variables 717 largest shift/esd in final cycle 0.00
R(F0) 0.048
RJF0 2) 0.113 goodness of fit 0.932
1 Otwinowski Z. & Minor, W. Methods Enzymol. 1997, 276, 307
A comparison of the calculated XRPD and experimental XRPD is shown is Figure 5. Form B is thermodynamically the most stable form as determined by interconversion slurries with Forms A and C-E.
TG analysis (Figure 6) demonstrated a weight loss of <0.2% at 147 0C indicating that Form B is non-solvated. DSC data (Figure 6) revealed a single endothermic transition with a peak maximum at about 161 0C. This endotherm is attributed to a melt base on hot-stage microscopy.
Automated moisture sorption/desorption analysis of Form B sample showed an insignificant weight gain of 0.15% at 95% RH. Upon desporption to 5% RH, the sample returned to its initial mass.
Example 3. Form C:
Form C was generated by slowly cooling a saturated acetonitrile solution of Formula I or from a fast evaporation of an acetonitrile solution of Formula I. There was about 0.6% of weight loss by TG analysis suggesting that Form C is anhydrous and non-solvated. The material exhibited a major endotherm at about 157 0C and a minor endothermic event at about 170 0C (Figure 7). The first endotherm is attributed to the melt based on hot-stage microscopy. The NMR spectrum of Form C material conforms to the structure of Formula I and no solvent signals were observed. A representative XRPD pattern (Shimadzu XRD- 6000) of Form C is shown in Figure 8. The peaks in the list below are selected from XRPD images that represent clear signals above the noise level. Peak positions can be +/- 0.2 °2theta.
Example 4. Form D:
In one method, Form D was generated by heating Form A to a boiling (142 0C) in din-butyl ether (25 mL/g of Form A material). The mixture was cooled to 90 + 5 0C and seed crystals of Form A were added. The mixture was stirred at 90 + 5 0C for 2 hours then cooled to 22 0C over 3 hours. The resulting solid was collected by filtration, washed with di-n-butyl ether and heptane, and dried in a vacuum oven.
In another method, Form D material was generated during VT-XRPD experiments utilizing Form C as starting material.
The DSC data showed a major endotherm at about 169 0C (endothermic maximum) (Figure 9). A representative XRPD pattern (In el XRG-3000) of Form D is shown in Figure 10. A comparison of XRPD patterns for Form A-D is shown in Figure 11. The peaks in the list below are selected from XRPD images that represent clear signals above the noise level. Peak positions can be +/- 0.2 °2theta.
*Weak signals
Example 5. Form E:
Crystalline Form E was made by adding tetrahyrofuran (THF) to 2-Amino-5-(2,2- dimethyl-propionyl)-4-{2-[5-(N,N'-ethoxycarbonyl-2-methylprop-2-yl) phosphonamido] furanylj-thiazole [2:1 (vol:wt) THF: Formula I]. The solution was heated to 40 0C. N- heptane [10:1 (vol:wt) heptane: Formula I] was added rapidly while maintaining the temperature above 40 0C. The mixture was cooled to ambient temperature and the filter cake was washed with n-heptane and dried under vacuum at 45-50 0C. A representative XRPD pattern of Form E is shown in Figure 12. The peaks in the list below are selected from XRPD images that represent clear signals above the noise level. Peak positions can be +/- 0.2 °2theta.
* Weak signals
Example 6. Additional Methods: Table 2. below lists additional methods that can be used to prepare crystalline forms of
Formula I.
Table 1. Methods to produce crystalline forms of Formula I. Column three lists the crystalline form produced using the solvent and crystallization conditions of columns one and two, respectively. Abbreviations: SE = slow evaporation; SC = slow cool; FE = fast evaporation; RT = room temperature; VO = vacuum oven.
Example 7. Amorphous 2-amino-5-(2,2-dimethylpropionyl)-4-{[5-(N,N'-(2-ethoxy- carbonylprop-2-yl)phosphonamido] furan-2-yl}thiazole:
Amorphous material of Formula I can be produced by lyophilizing the compound of Formula I in a 1:1 or 2:1 mixture (vol:vol) of l,4-dioxane:H2O.
Claims
1. A crystalline form of a compound of Formula 1
(I)-
2. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.3, 14.2, 14.9, 16 and 25.3.
3. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.3, 14.2, 16.0 and 25.3.
4. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.3, 12.6, 13.1 and 25.3, but not at 11.9 or 16.5.
5. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.3, 12.6, 13.1 and 25.3, but not at 6.4 or 21.4.
6. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 12.6, 13.1 and 25.3, but not at 7.8, 1 1.9 or 16.5.
7. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 13.1, 14.9, 20.8 and 25.3, but not at 11.9 or 21.4.
8. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 12.6, 17.2, 20.8 and 25.3, but not at 10.0, 1 1.9 or 16.5.
9. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.3, 12.6, 13.1, 14.2, 14.9, 17.2, 20.8 and 25.3, but not at 11.9.
10. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.3, 11.2, 12.6, 13.1, 13.5, 14.2, 14.7, 14.9, 16.0, 17.0, 17.2, 17.4, 18.3, 18.9, 19.6, 20.0, 20.2, 20.8, 22.6, and 25.3
11. The crystalline form of claim 10 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.8, 10.0 11.1, 11.5, 18.0, 18.8, and 21.5.
12. The crystalline form of claim 10 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.8 and 10.0.
13. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.8.
14. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 10.0.
15. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 5.7, 16.2, 18.8 and 21.5.
16. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.8 or 10.0 or 11.5, but not at 7.2 or 13.1.
17. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.8, 10.0, 11.1, 13.6, 16.2,
18.0, 20.2, and 21.5.
18. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 5.7, 7.8, 9.4, 10.0, 1 1.1, 11.5,
12.1, 12.4, 13.6, 14.2, 15.5, 16.2, 16.9, 18.0, 18.8, 19.9, 20.2, 20.9, 21.5, 22.4, 23.2, 24.3, 25.9 and 28.1.
19. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.8, 10.0, 11.1, 11.5, 13.6,
16.2, 18.0, 18.8, 20.2 and 21.5.
20. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.8, 9.4, 10.0, 11.1, 11.5, 12.1,
12.4, 13.6, 16.2, 16.9, 18.0, 18.8, 19.9, 20.2, 22.4 and 23.2.
21. The crystalline form of claim 1 , characterized by unit cell parameters approximately equal to the following: cell dimensions a = 11.4905(4)A, b = 16.3218(1O)A, c = 30.8664(17)A; space group P2i/c(No.l4); β, = 93.393(3).
22. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.2, 11.0 and 24.7.
23. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.2, 11.0, 13.1 24.7 and 27.7.
24. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.2, 11.0, 12.3, 13.1, 14.8,
16.5, 21.4, 24.7 and 27.7.
25. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.2, 11.0, 13.1 , 21.4 and 24.7.
26. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.2, 11.0 and 16.5.
27. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.2, 21.4 and 24.7.
28. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.2, 11.0, 13.1, 16.5, 21.4, 24.7, 26.5 and 27.7.
29. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 6.4, 7.1, 12.6 and 20.2.
30. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 6.4, 7.1, 11.9, 12.6, 13.1, 17.5, 19.3 and 20.2.
31. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 6.4.
32. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.1 and 12.6 but not at 7.8, 9.2, 11.0 or 16.0.
33. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 6.4, 7.1, 11.9 and 12.6, but not at 7.8 or 11.0.
34. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.2, 9.2, 1 1.3, 12.5, 14.0 and 17.9 but not at 25.3.
35. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.2, 12.5 and 17.9, but not at 6.4, 7.8, 24.7 or 25.3.
36. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.2, 9.2, 11.3, 12.5, 13.5, 14.0, 17.4 and 17.9 but not at 6.4 or 25.3.
37. The crystalline form of claim 1 having an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2-theta angles at 7.2, 9.2, 1 1.3, 12.1, 12.5, 13.5, 14.0, 14.7, 14.9, 15.1, 17.4, 17.9, 18.9 and 20.1 but not at 25.3.
38. A composition consisting essentially of the crystalline form of claim 1.
39. A composition consisting essentially of the crystalline form of any one of claims 2 -37.
40. A pharmaceutical composition comprising the crystalline form of claim 1 and a pharmaceutically acceptable carrier or excipient.
41. A pharmaceutical composition comprising a crystalline form of any one of claims 2 -37.
42. The crystalline form of any one claims 1-37 for the manufacture of a medicament for the prevention or treatment of a clinical condition for which an FBPase inhibitor(s) is indicated.
43. The crystalline form of any one claims 1-37 for the manufacture of a medicament for the treatment, prevention or reduction of the time to onset of a disease or
condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels.
44. A method of treating, preventing or reducing the time to onset of a disease or condition responsive to inhibition of gluconeogenesis or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount of the crystalline form of any one of claims 2-37.
45. A method of treating, preventing or reducing the time to onset of Type I diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of the crystalline form of any one of claims 2-37.
46. A method of treating, preventing or reducing the time to onset of Type II diabetes, the method comprising the step of administering to an animal a therapeutically effective amount of the crystalline form of any one of claims 2-37.
47. A method of treating, preventing or reducing the time to onset of Metabolic Syndrome X, the method comprising the step of administering to an animal a therapeutically effective amount of the crystalline form of any one of claims 2-37.
48. A method of treating, preventing or reducing the time to onset of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount of the crystalline form of any one of claims 2-37.
49. A method of treating, preventing or reducing the time to onset of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount of the crystalline form of any one of claims 2-37.
50. A method of treating, preventing or reducing the time to onset of hyperglycemia, the method comprising the step of administering to an animal a therapeutically effective amount of the crystalline form of any one of claims 2-37.
51. A method of treating, preventing or reducing the time to onset of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount of the crystalline form of any one of claims 2-37.
52. A method of treating, preventing or reducing the time to onset of increased or excessive hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount of the crystalline form of any one of claims 2-37.
53. A process of making a crystalline form of Formula I selected from Forms A-E, wherein said process comprises the step of combining the compound of Formula I with a solvent to form a mixture.
54. The process of claim 52 wherein said solvent is selected from tetrahydrofuran, methanol, acetronitrile, di-n-butyl ether, ethanol, ethyl acetate, heptane, 2-propyl ether, water, acetone, heptane, dichloromethane or a combination of any one or more of said solvents.
55. The process of claim 50, wherein said process further comprises a step of subjecting the mixture to conditions that cause said solvent to evaporate.
56. The process of claim 50, wherein said process further comprises a step of heating and cooling the mixture.
57. The process of claim 50, wherein said process further comprises the step of adding an antisolvent to said mixture.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94968107P | 2007-07-13 | 2007-07-13 | |
| US60/949,681 | 2007-07-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2009012039A2 true WO2009012039A2 (en) | 2009-01-22 |
| WO2009012039A3 WO2009012039A3 (en) | 2009-03-19 |
Family
ID=40260294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2008/068558 WO2009012039A2 (en) | 2007-07-13 | 2008-06-27 | Crystalline polymorphs |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2009012039A2 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
| WO2011161030A1 (en) | 2010-06-21 | 2011-12-29 | Sanofi | Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators |
| WO2012004269A1 (en) | 2010-07-05 | 2012-01-12 | Sanofi | (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals |
| WO2012004270A1 (en) | 2010-07-05 | 2012-01-12 | Sanofi | Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament |
| WO2012010413A1 (en) | 2010-07-05 | 2012-01-26 | Sanofi | Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6756360B1 (en) * | 1998-12-24 | 2004-06-29 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes |
| WO2006023515A2 (en) * | 2004-08-18 | 2006-03-02 | Metabasis Therapeutics, Inc. | Novel thiazole inhibitors of fructose 1,6-bisphosphatase |
-
2008
- 2008-06-27 WO PCT/US2008/068558 patent/WO2009012039A2/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6756360B1 (en) * | 1998-12-24 | 2004-06-29 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes |
| WO2006023515A2 (en) * | 2004-08-18 | 2006-03-02 | Metabasis Therapeutics, Inc. | Novel thiazole inhibitors of fructose 1,6-bisphosphatase |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
| WO2011161030A1 (en) | 2010-06-21 | 2011-12-29 | Sanofi | Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators |
| WO2012004269A1 (en) | 2010-07-05 | 2012-01-12 | Sanofi | (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals |
| WO2012004270A1 (en) | 2010-07-05 | 2012-01-12 | Sanofi | Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament |
| WO2012010413A1 (en) | 2010-07-05 | 2012-01-26 | Sanofi | Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009012039A3 (en) | 2009-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104918936B (en) | The pyridine-2-carboxamide compound being substituted as apoptosis signal regulating kinase inhibitor | |
| JP5584705B2 (en) | Crystal form of R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5-hydroxymethyloxazolidine-2-one phosphate | |
| WO2009012039A2 (en) | Crystalline polymorphs | |
| JP5400387B2 (en) | 1-benzoyl-4- [2- [4-methoxy-7- (3-methyl-1H-1,2,4-triazol-1-yl) -1-[(phosphonooxy) methyl] -1H-pyrrolo [2 , 3-C] pyridin-3-yl] -1,2-dioxoethyl] -piperazine | |
| CN109422752A (en) | One kind has inhibition and the active compound of bruton's tyrosine protein kinase B tk of degrading | |
| US11117875B2 (en) | Crystalline forms, preparation methods and pharmaceutical compositions of ozanimod | |
| TWI703143B (en) | Crystalline forms of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro〔 indazole-5,4'-piperidine 〕-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid | |
| JP2016512518A (en) | Solid form of Vemurafenib hydrochloride | |
| US20210053951A1 (en) | Salt Forms Of 4-Cyano-N-(4,4-Dimethylcyclohex-1-EN-1-YL)-6-(2,2,6,6-Tetramethyltetrahydro-2H-Pyran-4-YL)Pyridin-3-YL)-1H-Imidazole-2-Carboximide | |
| US6664267B1 (en) | Crystalline fluoroquinolone arginine salt form | |
| US10189870B2 (en) | Crystalline form of oxazolidinone antibiotics and preparation method, composition and use thereof | |
| CN113966332A (en) | Polymorphic substance of CDK9 inhibitor and preparation method and application thereof | |
| WO2019134455A1 (en) | Novel crystal form of acalabrutinib and preparation method and use thereof | |
| CN109937203A (en) | One kind has inhibition and the active compound of tyrosine protein kinase JAK1 or JAK2 of degrading | |
| US11149013B2 (en) | Crystal form of urate transporter 1 inhibitor and preparation method and use thereof | |
| WO2007149568A2 (en) | N- (4-chl0r0-3-methyl-5-is0xaz0lyl) -2- [2-methyl-4, 5- (methylenedioxy) phenylacetyl] -thiophene-3-sulfonamide | |
| TW202003467A (en) | Novel salt forms of URAT-1 inhibitors | |
| US8217172B2 (en) | Solid forms of 1-ethyl-3-(5-(5-fluoropyridin-3-yl)-7-(pyrimidin-2-yl)-1H-benzo[d]imidazol-2-yl)urea | |
| TWI752980B (en) | Crystalline forms of 4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide | |
| US20200345647A1 (en) | Dosage forms comprising a plasma kallikrein inhibitor | |
| US20190144474A1 (en) | Novel crystalline forms | |
| KR20230048004A (en) | Oxadiazole compound, preparation method thereof, pharmaceutical composition and use thereof | |
| WO2018130226A1 (en) | New crystal form of riociguat, preparation method and use thereof | |
| CN117567381A (en) | Bishydrazide HSL inhibitor, preparation method and application thereof | |
| US20190248788A1 (en) | Abt-199 addition salt and crystal form thereof, preparation method thereof, and pharmaceutical composition thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08781092 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08781092 Country of ref document: EP Kind code of ref document: A2 |